Document
false--12-31Q220190000832101IDEX CORP /DE/2934000351000341500067900022793296981264090169785P1Y3710003680003610003590006709000677800000.8601.000.0115000000090112028899579900.950.050.950.050.950.050.217680000005050004570004380004350000.015000000000P3Y0.03110.03170.02620.03040.02280.02010.02370.02531415925114114329014749036981019143 0000832101 2019-01-01 2019-06-30 0000832101 2019-07-23 0000832101 2019-06-30 0000832101 2018-12-31 0000832101 2019-04-01 2019-06-30 0000832101 2018-04-01 2018-06-30 0000832101 2018-01-01 2018-06-30 0000832101 2018-01-01 2018-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2017-12-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-04-01 2018-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31 0000832101 us-gaap:TreasuryStockMember 2018-03-31 0000832101 2017-12-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000832101 us-gaap:AccountingStandardsUpdate201802Member 2018-01-01 2018-03-31 0000832101 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-04-01 2018-06-30 0000832101 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000832101 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000832101 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0000832101 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 2018-03-31 0000832101 us-gaap:RetainedEarningsMember 2017-12-31 0000832101 2018-03-31 0000832101 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000832101 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0000832101 2018-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000832101 us-gaap:RetainedEarningsMember 2018-06-30 0000832101 us-gaap:RetainedEarningsMember 2018-03-31 0000832101 us-gaap:TreasuryStockMember 2018-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000832101 us-gaap:TreasuryStockMember 2017-12-31 0000832101 us-gaap:TreasuryStockMember 2018-12-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000832101 2019-01-01 2019-03-31 0000832101 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0000832101 us-gaap:TreasuryStockMember 2019-03-31 0000832101 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2018-12-31 0000832101 us-gaap:RetainedEarningsMember 2019-03-31 0000832101 2019-03-31 0000832101 us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000832101 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000832101 us-gaap:RetainedEarningsMember 2018-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-06-30 0000832101 us-gaap:RetainedEarningsMember 2019-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0000832101 us-gaap:TreasuryStockMember 2019-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000832101 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000832101 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-06-30 0000832101 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000832101 iex:FingerLakesInstrumentationFLIMember 2018-07-23 2018-07-23 0000832101 iex:FingerLakesInstrumentationFLIMember 2018-07-23 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2018-12-31 0000832101 us-gaap:CorporateNonSegmentMember 2018-12-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2018-12-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2018-12-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2018-04-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2018-04-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember 2018-04-01 2018-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesIncludedinOtherGeographicalAreasMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesIncludedinOtherGeographicalAreasMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesIncludedinOtherGeographicalAreasMember iex:FireAndSafetyDiversifiedProductsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesIncludedinOtherGeographicalAreasMember iex:FluidAndMeteringTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesIncludedinOtherGeographicalAreasMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesIncludedinOtherGeographicalAreasMember iex:HealthAndScienceTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FluidAndMeteringTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FireAndSafetyDiversifiedProductsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:HealthAndScienceTechnologiesMember 2019-04-01 2019-06-30 0000832101 2018-01-01 0000832101 iex:BilledReceivablesMember 2019-06-30 0000832101 iex:BilledReceivablesMember 2018-01-01 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:NorthAmericaExcludingUnitedStatesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember country:US iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:EuropeMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember srt:AsiaMember iex:FluidAndMeteringTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember iex:HealthAndScienceTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:PumpsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:PumpsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:PumpsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:FireandSafetyMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:FireandSafetyMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:FireandSafetyMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:ValvesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:FireandSafetyMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:ValvesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:ValvesMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:ValvesMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:PumpsMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember 2019-04-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2018-01-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2018-04-01 2018-06-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2019-04-01 2019-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember 2018-01-01 2018-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember 2018-04-01 2018-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredOverTimeMember 2018-04-01 2018-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember 2019-04-01 2019-06-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember us-gaap:TransferredOverTimeMember 2018-01-01 2018-06-30 0000832101 us-gaap:PatentsMember 2018-12-31 0000832101 iex:OtherAmortizableIntangibleAssetsMember 2019-06-30 0000832101 us-gaap:UnpatentedTechnologyMember 2019-01-01 2019-06-30 0000832101 us-gaap:TradeNamesMember 2019-01-01 2019-06-30 0000832101 iex:AkronBrasstradenameMember 2019-06-30 0000832101 iex:OtherAmortizableIntangibleAssetsMember 2018-12-31 0000832101 us-gaap:UnpatentedTechnologyMember 2019-06-30 0000832101 us-gaap:TradeNamesMember 2019-06-30 0000832101 iex:AkronBrasstradenameMember 2018-12-31 0000832101 us-gaap:UnpatentedTechnologyMember 2018-12-31 0000832101 iex:BanjoTradeNameMember 2018-12-31 0000832101 us-gaap:PatentsMember 2019-06-30 0000832101 us-gaap:CustomerRelationshipsMember 2019-06-30 0000832101 us-gaap:CustomerRelationshipsMember 2018-12-31 0000832101 us-gaap:PatentsMember 2019-01-01 2019-06-30 0000832101 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0000832101 iex:BanjoTradeNameMember 2019-06-30 0000832101 iex:OtherAmortizableIntangibleAssetsMember 2019-01-01 2019-06-30 0000832101 us-gaap:TradeNamesMember 2018-12-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2019-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2019-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2018-12-31 0000832101 iex:HealthAndScienceTechnologiesMember 2018-12-31 0000832101 iex:FluidAndMeteringTechnologiesMember 2019-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2018-12-31 0000832101 iex:FourPointFivePercentageSeniorNotesMember us-gaap:SeniorNotesMember 2019-06-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2019-06-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0000832101 us-gaap:RevolvingCreditFacilityMember 2019-06-30 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2019-06-30 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0000832101 iex:FourPointFivePercentageSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0000832101 us-gaap:RevolvingCreditFacilityMember 2018-12-31 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2019-06-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2016-06-13 0000832101 srt:MinimumMember 2019-06-30 0000832101 us-gaap:RevolvingCreditFacilityMember 2019-05-31 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2016-06-13 0000832101 us-gaap:RevolvingCreditFacilityMember 2015-06-23 0000832101 us-gaap:RevolvingCreditFacilityMember iex:SwinglineLoansMember 2019-05-31 0000832101 srt:MaximumMember 2019-01-01 2019-06-30 0000832101 srt:MaximumMember us-gaap:SeniorNotesMember 2019-06-30 0000832101 us-gaap:RevolvingCreditFacilityMember us-gaap:StandbyLettersOfCreditMember 2019-05-31 0000832101 iex:FourPointTwoPercentageSeniorNotesMember 2019-06-30 0000832101 iex:FourPointFivePercentageSeniorNotesMember 2019-06-30 0000832101 srt:MinimumMember 2016-06-13 0000832101 iex:For12MonthsinConnectionwithCertainAcquisitionsMember 2019-01-01 2019-06-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember 2019-06-30 0000832101 iex:ThreePointTwoPercentSeniorNotesMember 2019-06-30 0000832101 us-gaap:RevolvingCreditFacilityMember 2019-05-31 2019-05-31 0000832101 iex:InterestRateExchangeAgreementExpiringTwoThousandTenandElevenMember 2010-01-01 2011-12-31 0000832101 us-gaap:ForeignExchangeForwardMember 2018-01-01 2018-06-30 0000832101 us-gaap:InterestRateContractMember 2011-12-31 0000832101 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-06-30 0000832101 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-04-01 2018-06-30 0000832101 iex:FourPointFivePercentageSeniorNotesMember 2011-12-31 0000832101 iex:FourPointTwoPercentageSeniorNotesMember 2011-12-31 0000832101 country:CH 2018-04-01 2018-04-30 0000832101 us-gaap:ForeignExchangeForwardMember 2018-12-31 0000832101 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000832101 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000832101 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000832101 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000832101 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000832101 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000832101 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000832101 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0000832101 iex:FourPointTwoPercentageSeniorNotesMember 2018-12-31 0000832101 iex:ThreePointTwoPercentSeniorNotesMember 2018-12-31 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000832101 iex:FourPointFivePercentageSeniorNotesMember 2018-12-31 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000832101 us-gaap:OtherNoncurrentLiabilitiesMember iex:FingerLakesInstrumentationFLIMember 2019-06-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember 2018-12-31 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000832101 us-gaap:EquipmentMember 2019-06-30 0000832101 us-gaap:BuildingMember 2019-06-30 0000832101 us-gaap:VehiclesMember 2019-06-30 0000832101 iex:BuildingAndEquipmentMember 2019-06-30 0000832101 us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:EmployeeSeveranceMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:EmployeeSeveranceMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:EmployeeSeveranceMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-06-30 0000832101 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-06-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-04-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-04-01 2019-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-04-01 2019-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2018-01-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2018-04-01 2018-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-01-01 2019-06-30 0000832101 2015-12-01 2015-12-01 0000832101 2018-07-01 2018-07-31 0000832101 2014-11-06 0000832101 iex:CashsettledRestrictedStockMember 2019-01-01 2019-06-30 0000832101 iex:CashsettledRestrictedStockMember 2018-12-31 0000832101 iex:CashsettledRestrictedStockMember 2019-06-30 0000832101 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000832101 us-gaap:PerformanceSharesMember 2018-04-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember 2018-01-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember 2019-04-01 2019-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2019-06-30 0000832101 iex:EmployeesandNonemployeeDirectorsMember us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0000832101 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0000832101 us-gaap:PerformanceSharesMember 2019-02-01 2019-02-28 0000832101 us-gaap:PerformanceSharesMember 2019-06-30 0000832101 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000832101 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000832101 us-gaap:PerformanceSharesMember 2018-12-31 0000832101 iex:CashsettledRestrictedStockMember 2019-04-01 2019-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000832101 iex:CashsettledRestrictedStockMember 2018-04-01 2018-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000832101 iex:CashsettledRestrictedStockMember 2018-01-01 2018-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000832101 us-gaap:RestrictedStockMember 2018-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2018-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-31 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-01 2018-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0000832101 srt:MaximumMember 2019-06-30 0000832101 iex:VelcoraHoldingABMember us-gaap:SubsequentEventMember 2019-07-18 2019-07-18 0000832101 iex:VelcoraHoldingABMember 2018-01-01 2018-12-31 xbrli:pure xbrli:shares iex:segment iso4217:USD iso4217:USD xbrli:shares iex:instrument iex:covenant iex:option iso4217:EUR
Table of Contents


 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________ 
Form 10-Q
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 
For the quarterly period ended
June 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 1-10235
IDEX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
 
 
Delaware
 
36-3555336
 
(State or other jurisdiction of
incorporation or organization)

 
(I.R.S. Employer
Identification No.)
 
 
 
 
 
 
 
1925 West Field Court,
Suite 200,
Lake Forest,
Illinois
 
60045
 
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number: (847498-7070
Title of Each Class
 
Trading Symbol(s)
 
Name of Each Exchange on Which Registered
Common Stock, par value $.01 per share
 
IEX
 
New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer
 
Accelerated filer  
 
Non-accelerated filer 
 
Smaller reporting company
 
 
 
 
 
 
 
Emerging growth company
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 



Table of Contents


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes     No   
Number of shares of common stock of IDEX Corporation outstanding as of July 23, 2019: 75,847,167.
 


Table of Contents


TABLE OF CONTENTS
 
 
Item 1.
 
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
Item 4.
 
 
 
Item 1.
Item 2.
Item 6.


Table of Contents


PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements

IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
 
 
June 30, 2019
 
December 31, 2018
ASSETS
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
543,189

 
$
466,407

Receivables, less allowance for doubtful accounts of $6,778 at June 30, 2019 and $6,709 at December 31, 2018
326,358

 
312,192

Inventories
301,006

 
279,995

Other current assets
46,329

 
33,938

Total current assets
1,216,882

 
1,092,532

Property, plant and equipment - net
275,025

 
281,220

Goodwill
1,697,332

 
1,697,955

Intangible assets - net
365,741

 
383,327

Other noncurrent assets
85,235

 
18,823

Total assets
$
3,640,215

 
$
3,473,857

LIABILITIES AND SHAREHOLDERS’ EQUITY
 
 
 
Current liabilities
 
 
 
Trade accounts payable
$
160,579

 
$
143,196

Accrued expenses
162,838

 
187,536

Short-term borrowings
452

 
483

Dividends payable
37,922

 
33,446

Total current liabilities
361,791

 
364,661

Long-term borrowings
848,555

 
848,335

Deferred income taxes
140,147

 
128,007

Other noncurrent liabilities
177,681

 
138,214

Total liabilities
1,528,174

 
1,479,217

Commitments and contingencies

 

Shareholders’ equity
 
 
 
Preferred stock:
 
 
 
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None

 

Common stock:
 
 
 
Authorized: 150,000,000 shares, $.01 per share par value
 
 
 
Issued: 89,957,990 shares at June 30, 2019 and 90,112,028 shares at December 31, 2018
900

 
901

Additional paid-in capital
749,009

 
738,339

Retained earnings
2,489,911

 
2,342,079

Treasury stock at cost: 14,114,329 shares at June 30, 2019 and 14,159,251 shares at December 31, 2018
(1,002,870
)
 
(957,454
)
Accumulated other comprehensive income (loss)
(124,909
)
 
(129,225
)
Total shareholders’ equity
2,112,041

 
1,994,640

Total liabilities and shareholders’ equity
$
3,640,215

 
$
3,473,857

See Notes to Condensed Consolidated Financial Statements

1

Table of Contents


IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
 
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Net sales
$
642,099

 
$
634,360

 
$
1,264,330

 
$
1,246,684

Cost of sales
349,762

 
346,993

 
688,159

 
682,665

Gross profit
292,337

 
287,367

 
576,171

 
564,019

Selling, general and administrative expenses
134,928

 
137,548

 
270,980

 
275,875

Restructuring expenses
2,126

 
1,988

 
2,126

 
3,630

Operating income
155,283

 
147,831

 
303,065

 
284,514

Other (income) expense - net
(378
)
 
(50
)
 
(518
)
 
(4,499
)
Interest expense
11,011

 
11,140

 
21,932

 
22,140

Income before income taxes
144,650

 
136,741

 
281,651

 
266,873

Provision for income taxes
31,441

 
29,615

 
58,174

 
60,789

Net income
$
113,209

 
$
107,126

 
$
223,477

 
$
206,084

 
 
 
 
 
 
 
 
Basic earnings per common share
$
1.50

 
$
1.40

 
$
2.96

 
$
2.69

Diluted earnings per common share
$
1.48

 
$
1.38

 
$
2.92

 
$
2.65

 
 
 
 
 
 
 
 
Share data:
 
 
 
 
 
 
 
Basic weighted average common shares outstanding
75,460

 
76,539

 
75,450

 
76,479

Diluted weighted average common shares outstanding
76,387

 
77,704

 
76,334

 
77,722

See Notes to Condensed Consolidated Financial Statements

2

Table of Contents


IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
(unaudited)
 
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Net income
$
113,209

 
$
107,126

 
$
223,477

 
$
206,084

Other comprehensive income (loss):
 
 
 
 
 
 
 
Reclassification adjustments for derivatives, net of tax
1,224

 
1,259

 
2,451

 
2,520

Pension and other postretirement adjustments, net of tax
1,256

 
1,296

 
2,518

 
2,709

Cumulative translation adjustment
2,628

 
(62,645
)
 
(653
)
 
(35,067
)
Other comprehensive income (loss)
5,108

 
(60,090
)
 
4,316

 
(29,838
)
Comprehensive income
$
118,317

 
$
47,036

 
$
227,793

 
$
176,246

See Notes to Condensed Consolidated Financial Statements

3

Table of Contents


IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands except share amounts)
(unaudited)
 
 
 
 
 
 
Accumulated Other Comprehensive
Income (Loss)
 
 
 
 
 
Common
Stock and
Additional
Paid-In Capital
 
Retained
Earnings
 
Cumulative
Translation
Adjustment
 
Retirement
Benefits
Adjustment
 
Cumulative
Unrealized Gain (Loss) on
Derivatives
 
Treasury
Stock
 
Total
Shareholders’
Equity
Balance, December 31, 2018
$
739,240

 
$
2,342,079

 
$
(94,420
)
 
$
(22,740
)
 
$
(12,065
)
 
$
(957,454
)
 
$
1,994,640

Net income

 
110,268

 

 

 

 

 
110,268

Adjustment for adoption of ASU 2016-02

 
28

 

 

 

 

 
28

Cumulative translation adjustment

 

 
(3,281
)
 

 

 

 
(3,281
)
Net change in retirement obligations (net of tax of $438)

 

 

 
1,262

 

 

 
1,262

Net change on derivatives designated as cash flow hedges (net of tax of $361)

 

 

 

 
1,227

 

 
1,227

Issuance of 264,090 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $3,415)

 

 

 

 

 
8,870

 
8,870

Repurchase of 369,810 shares of common stock

 

 

 

 

 
(51,706
)
 
(51,706
)
Shares surrendered for tax withholding

 

 

 

 

 
(11,479
)
 
(11,479
)
Share-based compensation
5,403

 

 

 

 

 

 
5,403

Balance, March 31, 2019
$
744,643

 
$
2,452,375

 
$
(97,701
)
 
$
(21,478
)
 
$
(10,838
)
 
$
(1,011,769
)
 
$
2,055,232

Net income

 
113,209

 

 

 

 

 
113,209

Cumulative translation adjustment

 

 
2,628

 

 

 

 
2,628

Net change in retirement obligations (net of tax of $435)

 

 

 
1,256

 

 

 
1,256

Net change on derivatives designated as cash flow hedges (net of tax of $359)

 

 

 

 
1,224

 

 
1,224

Issuance of 169,785 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $679)

 

 

 

 

 
11,891

 
11,891

Repurchase of 19,143 shares of common stock

 

 

 

 

 
(2,962
)
 
(2,962
)
Shares surrendered for tax withholding

 

 

 

 

 
(30
)
 
(30
)
Share-based compensation
5,266

 

 

 

 

 

 
5,266

Cash dividends declared - $1.00 per common share outstanding

 
(75,673
)
 

 

 

 

 
(75,673
)
Balance, June 30, 2019
$
749,909

 
$
2,489,911

 
$
(95,073
)
 
$
(20,222
)
 
$
(9,614
)
 
$
(1,002,870
)
 
$
2,112,041


See Notes to Condensed Consolidated Financial Statements






4

Table of Contents


IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Continued)
(in thousands except share amounts)
(unaudited)

 
 
 
 
 
Accumulated Other Comprehensive
Income (Loss)
 
 
 
 
 
Common
Stock and
Additional
Paid-In Capital
 
Retained
Earnings
 
Cumulative
Translation
Adjustment
 
Retirement
Benefits
Adjustment
 
Cumulative
Unrealized Gain (Loss) on
Derivatives
 
Treasury
Stock
 
Total
Shareholders’
Equity
Balance, December 31, 2017
$
717,808

 
$
2,057,915

 
$
(46,306
)
 
$
(29,154
)
 
$
(14,047
)
 
$
(799,674
)
 
$
1,886,542

Net income

 
98,958

 

 

 

 

 
98,958

Adjustment for adoption of ASU 2016-16

 
(645
)
 

 

 

 

 
(645
)
Adjustment for adoption of ASU 2018-02

 
6,435

 

 
(3,411
)
 
(3,024
)
 

 

Cumulative translation adjustment

 

 
27,578

 

 

 

 
27,578

Net change in retirement obligations (net of tax of $505)

 

 

 
1,413

 

 

 
1,413

Net change on derivatives designated as cash flow hedges (net of tax of $371)

 

 

 

 
1,261

 

 
1,261

Issuance of 227,932 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $2,934)

 

 

 

 

 
6,590

 
6,590

Shares surrendered for tax withholding

 

 

 

 

 
(10,750
)
 
(10,750
)
Share-based compensation
5,938

 

 

 

 

 

 
5,938

Balance, March 31, 2018
$
723,746

 
$
2,162,663

 
$
(18,728
)
 
$
(31,152
)
 
$
(15,810
)
 
$
(803,834
)
 
$
2,016,885

Net income

 
107,126

 

 

 

 

 
107,126

Cumulative translation adjustment

 

 
(62,645
)
 

 

 

 
(62,645
)
Net change in retirement obligations (net of tax of $457)

 

 

 
1,296

 

 

 
1,296

Net change on derivatives designated as cash flow hedges (net of tax of $368)

 

 

 

 
1,259

 

 
1,259

Issuance of 96,981 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $351)

 

 

 

 

 
7,026

 
7,026

Repurchase of 147,490 shares of common stock

 

 

 

 

 
(20,494
)
 
(20,494
)
Share-based compensation
5,014

 

 

 

 

 

 
5,014

Cash dividends declared - $0.86 per common share outstanding

 
(66,316
)
 

 

 

 

 
(66,316
)
Balance, June 30, 2018
$
728,760

 
$
2,203,473

 
$
(81,373
)
 
$
(29,856
)
 
$
(14,551
)
 
$
(817,302
)
 
$
1,989,151


See Notes to Condensed Consolidated Financial Statements

5

Table of Contents


IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Six Months Ended June 30,
 
2019
 
2018
Cash flows from operating activities
 
 
 
Net income
$
223,477

 
$
206,084

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
19,870

 
19,957

Amortization of intangible assets
17,953

 
20,667

Amortization of debt issuance expenses
669

 
664

Share-based compensation expense
14,413

 
13,252

Deferred income taxes
10,685

 
(3,021
)
Non-cash interest expense associated with forward starting swaps
3,171

 
3,259

Changes in (net of the effect from acquisitions):
 
 
 
Receivables
(14,177
)
 
(40,044
)
Inventories
(21,007
)
 
(28,011
)
Other current assets
(12,382
)
 
17,798

Trade accounts payable
17,276

 
5,432

Accrued expenses
(39,602
)
 
(21,131
)
Other - net
(508
)
 
(2,480
)
Net cash flows provided by operating activities
219,838

 
192,426

Cash flows from investing activities
 
 
 
Purchases of property, plant and equipment
(25,742
)
 
(20,968
)
Purchase of intellectual property

 
(4,000
)
Proceeds from disposal of fixed assets
780

 

Other - net
501

 
(861
)
Net cash flows used in investing activities
(24,461
)
 
(25,829
)
Cash flows from financing activities
 
 
 
Dividends paid
(71,283
)
 
(61,916
)
Proceeds from stock option exercises
20,761

 
13,616

Repurchases of common stock
(54,668
)
 
(19,499
)
Shares surrendered for tax withholding
(11,509
)
 
(10,750
)
Settlement of foreign exchange contracts

 
6,593

Other - net
(1,929
)
 

Net cash flows used in financing activities
(118,628
)
 
(71,956
)
Effect of exchange rate changes on cash and cash equivalents
33

 
(11,840
)
Net increase in cash
76,782

 
82,801

Cash and cash equivalents at beginning of year
466,407

 
375,950

Cash and cash equivalents at end of period
$
543,189

 
$
458,751

 
 
 
 
Supplemental cash flow information
 
 
 
Cash paid for:
 
 
 
Interest
$
18,282

 
$
18,223

Income taxes
55,702

 
38,190

Significant non-cash activities:
 
 
 
Capital expenditures for construction of new leased facility

 
11,971


See Notes to Condensed Consolidated Financial Statements

6

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)


1.    Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX,” “we,” “our,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire year.

The Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Recently Adopted Accounting Standards

In February 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases, which set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The standard introduced a new lessee model that requires most leases to be recorded on the balance sheet and eliminates the required use of bright line tests from U.S. GAAP for determining lease classification. In July 2018, the FASB issued the following standards which clarified ASU 2016-02 and had the same effective date as the original standard: ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases (Topic 842): Targeted Improvements. ASU 2018-11 included an option to use the effective date of ASU 2016-02 as the date of initial application of transition as well as an option not to restate comparative periods in transition. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842): Codification Improvements, which also clarifies ASU 2016-02 and is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years.

The Company adopted this standard on January 1, 2019 using the optional transition method provided by the FASB in ASU 2018-11. As we did not restate comparative periods, the adoption had no impact on our previously reported results. We elected to use both the practical expedient that allowed us not to reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases as well as the practical expedient that allows us to treat the lease and non-lease components of a lease as a single lease component for all asset classes. We also elected to account for short-term leases in accordance with Accounting Standards Codification (“ASC”) 842-20-25-2. The adoption of this standard had a material impact on our condensed consolidated balance sheet due to the recognition of right of use assets and lease liabilities. Upon adoption, we recognized right of use assets and lease liabilities of approximately $68 million that reflected the present value of future lease payments. The adoption of this standard did not have a material impact on our condensed consolidated results of operations or cash flows. See Note 13 for further information.

2.    Acquisitions and Divestitures

All of the Company’s acquisitions of businesses have been accounted for under ASC 805, Business Combinations. Accordingly, the accounts of the acquired companies, after adjustments to reflect the fair values assigned to assets and liabilities, have been included in the Company’s condensed consolidated financial statements from their respective dates of acquisition. The results of operations of the acquired companies have been included in the Company’s condensed consolidated results since the date of each acquisition.

The Company incurred acquisition-related transaction costs of $0.4 million and $0.8 million in the three months ended June 30, 2019 and 2018, respectively, and $0.7 million and $1.5 million in the six months ended June 30, 2019 and 2018, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed transactions, pending transactions and potential transactions, including transactions that ultimately were not completed.


7

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

2018 Acquisition

On July 23, 2018, the Company acquired Finger Lakes Instrumentation (“FLI”), a technology leader in the design, development and production of low-noise cooled CCD and high speed, high-sensitivity Scientific CMOS cameras for the astronomy and life science markets. Headquartered in Lima, NY, FLI operates in our Health & Sciences Technologies segment. FLI was acquired for an aggregate purchase price of $23.6 million, consisting of $20.2 million in cash and contingent consideration valued at $3.4 million as of the opening balance sheet date. The contingent consideration is based on the achievement of financial objectives during the 24-month period following the close of the transaction. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $12.6 million and $7.9 million, respectively. Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business. The goodwill is deductible for tax purposes.

The Company finalized its allocation of the purchase price for the FLI acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.

3.    Business Segments

IDEX has three reportable business segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”).

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agriculture and energy industries.

The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded sealing components, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications.

The Fire & Safety/Diversified Products segment designs, produces and distributes firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.

Information on the Company’s business segments is presented below based on the nature of products and services offered. The Company evaluates performance based on several factors, of which sales, operating income and operating margin are the primary financial measures. Intersegment sales are accounted for at fair value as if the sales were to third parties.


8

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Net sales
 
 
 
 
 
 
 
Fluid & Metering Technologies
 
 
 
 
 
 
 
External customers
$
246,111

 
$
242,755

 
$
488,447

 
$
475,016

Intersegment sales
78

 
45

 
264

 
117

Total segment sales
246,189

 
242,800

 
488,711

 
475,133

Health & Science Technologies
 
 
 
 
 
 
 
External customers
232,172

 
227,367

 
456,860

 
448,334

Intersegment sales
81

 
36

 
683

 
144

Total segment sales
232,253

 
227,403

 
457,543

 
448,478

Fire & Safety/Diversified Products
 
 
 
 
 
 
 
External customers
163,816

 
164,238

 
319,023

 
323,334

Intersegment sales
227

 
62

 
1,179

 
139

Total segment sales
164,043

 
164,300

 
320,202

 
323,473

Intersegment elimination
(386
)
 
(143
)
 
(2,126
)
 
(400
)
Total net sales
$
642,099

 
$
634,360

 
$
1,264,330

 
$
1,246,684

Operating income
 
 
 
 
 
 
 
Fluid & Metering Technologies
$
74,146

 
$
71,228

 
$
146,012

 
$
137,394

Health & Science Technologies
56,763

 
52,569

 
110,917

 
104,375

Fire & Safety/Diversified Products
43,614

 
45,882

 
83,942

 
85,436

Corporate office
(19,240
)
 
(21,848
)
 
(37,806
)
 
(42,691
)
Total operating income
155,283

 
147,831

 
303,065

 
284,514

Interest expense
11,011

 
11,140

 
21,932

 
22,140

Other (income) expense - net
(378
)
 
(50
)
 
(518
)
 
(4,499
)
Income before income taxes
$
144,650

 
$
136,741

 
$
281,651

 
$
266,873

 
June 30,
2019
 
December 31,
2018
Assets
 
 
 
Fluid & Metering Technologies
$
1,128,514

 
$
1,107,777

Health & Science Technologies
1,375,385

 
1,329,368

Fire & Safety/Diversified Products
820,244

 
806,075

Corporate office
316,072

 
230,637

Total assets
$
3,640,215

 
$
3,473,857



4.    Revenue

IDEX is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. The Company’s products include industrial pumps, compressors, flow meters, injectors, valves and related controls for use in a wide variety of process applications; precision fluidics solutions, including pumps, valves, degassing equipment, corrective tubing, fittings and complex manifolds, optical filters and specialty medical equipment and devices for use in life science applications; precision-engineered equipment for dispensing, metering and mixing paints; and engineered products for industrial and commercial markets, including fire and rescue, transportation equipment, oil and gas, electronics and communications.


9

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Revenue is recognized when control of the promised products or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those products or providing those services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. We determine the appropriate revenue recognition for our contracts with customers by analyzing the type, terms and conditions of each contract or arrangement with a customer.

Disaggregation of Revenue

We have a comprehensive offering of products, including technologies, built to customers’ specifications that are sold in niche markets throughout the world. We disaggregate our revenue from contracts with customers by reporting unit and geographical region for each of our segments as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Revenue was attributed to geographic areas based on the location of the customer. The following tables present our revenue disaggregated by reporting unit and geographical region.

Revenue by reporting unit for the three and six months ended June 30, 2019 and 2018 was as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Energy
$
40,608

 
$
40,779

 
$
80,006

 
$
79,538

Valves
29,809

 
28,830

 
59,191

 
54,859

Water
65,148

 
65,171

 
126,280

 
124,011

Pumps
87,125

 
82,735

 
175,385

 
163,401

Agriculture
23,499

 
25,285

 
47,849

 
53,324

Intersegment elimination
(78
)
 
(45
)
 
(264
)
 
(117
)
Fluid & Metering Technologies
246,111

 
242,755

 
488,447

 
475,016

Scientific Fluidics & Optics
109,554

 
104,106

 
216,862

 
203,613

Sealing Solutions
46,431

 
51,634

 
96,937

 
105,336

Gast
37,399

 
30,903

 
71,308

 
59,415

Micropump
8,271

 
9,800

 
17,026

 
19,098

Material Processing Technologies
30,598

 
30,960

 
55,410

 
61,016

Intersegment elimination
(81
)
 
(36
)
 
(683
)
 
(144
)
Health & Science Technologies
232,172

 
227,367

 
456,860

 
448,334

Fire & Safety
103,257

 
99,940

 
202,705

 
196,152

BAND-IT
27,758

 
26,981

 
55,670

 
54,455

Dispensing
33,028

 
37,379

 
61,827

 
72,866

Intersegment elimination
(227
)
 
(62
)
 
(1,179
)
 
(139
)
Fire & Safety/Diversified Products
163,816

 
164,238

 
319,023

 
323,334

Total net sales
$
642,099

 
$
634,360

 
$
1,264,330

 
$
1,246,684




10

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Revenue by geographical region for the three and six months ended June 30, 2019 and 2018 was as follows:
 
Three Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
IDEX
U.S.
$
139,786

 
$
106,193

 
$
78,898

 
$
324,877

North America, excluding U.S.
14,628

 
5,497

 
6,418

 
26,543

Europe
43,949

 
65,798

 
43,813

 
153,560

Asia
32,353

 
50,502

 
26,744

 
109,599

Other (1)
15,473

 
4,263

 
8,170

 
27,906

Intersegment elimination
(78
)
 
(81
)
 
(227
)
 
(386
)
Total net sales
$
246,111

 
$
232,172

 
$
163,816

 
$
642,099

 
Three Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
IDEX
U.S.
$
139,347

 
$
97,544

 
$
75,747

 
$
312,638

North America, excluding U.S. (2)

 

 

 

Europe
40,097

 
74,023

 
43,702

 
157,822

Asia
34,899

 
48,240

 
30,065

 
113,204

Other (3)
28,457

 
7,596

 
14,786

 
50,839

Intersegment elimination
(45
)
 
(36
)
 
(62
)
 
(143
)
Total net sales
$
242,755

 
$
227,367

 
$
164,238

 
$
634,360

 
Six Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
IDEX
U.S.
$
277,935

 
$
205,244

 
$
153,575

 
$
636,754

North America, excluding U.S.
27,685

 
10,389

 
12,398

 
50,472

Europe
87,573

 
135,170

 
86,875

 
309,618

Asia
64,270

 
98,561

 
50,304

 
213,135

Other (1)
31,248

 
8,179

 
17,050

 
56,477

Intersegment elimination
(264
)
 
(683
)
 
(1,179
)
 
(2,126
)
Total net sales
$
488,447

 
$
456,860

 
$
319,023

 
$
1,264,330

 
Six Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
IDEX
U.S.
$
272,500

 
$
191,352

 
$
148,244

 
$
612,096

North America, excluding U.S. (2)

 

 

 

Europe
83,696

 
147,802

 
90,821

 
322,319

Asia
61,297

 
92,788

 
54,298

 
208,383

Other (3)
57,640

 
16,536

 
30,110

 
104,286

Intersegment elimination
(117
)
 
(144
)
 
(139
)
 
(400
)
Total net sales
$
475,016

 
$
448,334

 
$
323,334

 
$
1,246,684


(1) Other in 2019 includes: South America, Middle East, Australia and Africa.
(2) Revenue from North America, excluding U.S. of $15,631 from FMT, $4,038 from HST and $6,297 from FSDP were included in Other for the three months ended June 30, 2018. Revenue from North America, excluding U.S. of $29,219 from FMT, $7,358 from HST and $13,906 from FSDP were included in Other for the six months ended June 30, 2018.
(3) Other in 2018 includes: North America, excluding U.S., South America, Middle East, Australia and Africa.

11

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)


Contract Balances

The timing of revenue recognition, billings and cash collections results in customer receivables, advance payments and billings in excess of revenue recognized. Customer receivables include amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables on our Condensed Consolidated Balance Sheets. Amounts are billed in accordance with contractual terms or as work progresses in accordance with contractual terms. Unbilled amounts arise when the timing of billing differs from the timing of revenue recognized, such as when contract provisions require specific milestones to be met before a customer can be billed. Unbilled amounts primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and the revenue recognized exceeds the amount billed to the customer as there is not yet a right to payment in accordance with contractual terms. Unbilled amounts are recorded as a contract asset when the revenue associated with the contract is recognized prior to billing and derecognized when billed in accordance with the terms of the contract. Customer receivables are recorded at face amounts less an allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts for estimated losses as a result of customers’ inability to make required payments. Management evaluates the aging of the customer receivable balances, the financial condition of its customers, historical trends and the time outstanding of specific balances to estimate the amount of customer receivables that may not be collected in the future and records the appropriate provision.

The composition of Customer receivables was as follows:
 
June 30, 
 2019
 
December 31, 
 2018
Billed receivables
$
314,714

 
$
299,227

Unbilled receivables
12,034

 
14,492

Total customer receivables
$
326,748

 
$
313,719



Advance payments and billings in excess of revenue recognized are included in Deferred revenue which is classified as current or noncurrent based on the timing of when we expect to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on our Condensed Consolidated Balance Sheets. Advance payments and billings in excess of revenue recognized represent contract liabilities and are recorded when customers remit contractual cash payments in advance of us satisfying performance obligations under contractual arrangements, including those with performance obligations satisfied over time. Billings in excess of revenue recognized primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and revenue cannot yet be recognized as the Company has not completed the corresponding performance obligation. We generally receive advance payments from customers related to maintenance services which we recognize ratably over the service term. Contract liabilities are derecognized when revenue is recognized and the performance obligation is satisfied.

The composition of Deferred revenue was as follows:
 
June 30, 
 2019
 
December 31, 
 2018
Deferred revenue - current
$
11,861

 
$
8,055

Deferred revenue - noncurrent
2,512

 
3,027

Total deferred revenue
$
14,373

 
$
11,082



Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct product or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For our contracts that require complex design, manufacturing and installation activities that are not separately identifiable from other promises in the contract and, therefore, not distinct, the entire contract is accounted for as a single performance obligation. For our contracts that include distinct products or services that are substantially the same and have the same pattern of transfer to the customer over time, they are recognized as a series of distinct products or services. Certain of our contracts have multiple performance obligations for which we allocate the transaction price to each performance obligation using an estimate of the standalone selling price of each distinct product or service in the contract. For product sales, each product sold to a customer

12

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

generally represents a distinct performance obligation. In such cases, the observable standalone sales are used to determine the standalone selling price. In certain cases, we may be required to estimate standalone selling price using the expected cost plus margin approach, under which we forecast our expected costs of satisfying a performance obligation and then add an appropriate margin for that distinct product or service.

Our performance obligations are satisfied at a point in time or over time as work progresses. Performance obligations are supported by contracts with customers that provide a framework for the nature of the distinct products or services or bundle of products and services. We define service revenue as revenue from activities that are not associated with the design, development or manufacture of a product or the delivery of a software license.

Revenue from products and services transferred to customers at a point in time approximated 95% of total revenues in the three and six months ended June 30, 2019 and 2018. Revenue recognized at a point in time relates to the majority of our product sales. Revenue on these contracts is recognized when obligations under the terms of the contract with our customer are satisfied. Generally, this occurs with the transfer of control of the asset, which is in line with shipping terms.

Revenue from products and services transferred to customers over time approximated 5% of total revenues in the three and six months ended June 30, 2019 and 2018. Revenue earned by certain business units within the Water, Energy, Material Processing Technologies (“MPT”) and Dispensing reporting units is recognized over time because control transfers continuously to our customers. When accounting for over-time contracts, we use an input measure to determine the extent of progress towards completion of the performance obligation. For certain business units within the Water, Energy and MPT reporting units, revenue is recognized over time as work is performed based on the relationship between actual costs incurred to date for each contract and the total estimated costs for such contract at completion of the performance obligation (i.e. the cost-to-cost method). We believe this measure of progress best depicts the transfer of control to the customer which occurs as we incur costs on our contracts. Incurred cost represents work performed, which corresponds with the transfer of control to the customer. Contract costs include labor, material and overhead. Contract estimates are based on various assumptions to project the outcome of future events. These assumptions include labor productivity and availability; the complexity of the work to be performed; the cost and availability of materials; the performance of subcontractors; and the availability and timing of funding from the customer. Revenues, including estimated fees or profits, are recorded proportionally as costs are incurred. For certain business units within the Energy and Dispensing reporting units, revenue is recognized ratably over the contract term.

As a significant change in one or more of these estimates could affect the profitability of our contracts, we review and update our estimates regularly. Due to uncertainties inherent in the estimation process, it is reasonably possible that completion costs, including those arising from contract penalty provisions and final contract settlements, will be revised. Such revisions to costs and income are recognized in the period in which the revisions are determined as a cumulative catch-up adjustment. The impact of the adjustment on profit recorded to date on a contract is recognized in the period the adjustment is identified. Revenue and profit in future periods of contract performance are recognized using the adjusted estimate. If at any time the estimate of contract profitability indicates an anticipated loss on the contract, we recognize provisions for estimated losses on uncompleted contracts in the period in which such losses are determined.

The Company records allowances for discounts and product returns at the time of sale as a reduction of revenue as such allowances can be reliably estimated based on historical experience and known trends. The Company also offers product warranties (primarily assurance-type) and accrues its estimated exposure for warranty claims at the time of sale based upon the length of the warranty period, warranty costs incurred and any other related information known to the Company.

5.    Earnings Per Common Share

Earnings per common share (“EPS”) is computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents outstanding (diluted) during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, restricted stock and performance share units.

ASC 260, Earnings Per Share, concludes that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company

13

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

has determined that its outstanding shares of restricted stock are participating securities. Accordingly, EPS was computed using the two-class method prescribed by ASC 260.

Basic weighted average shares outstanding reconciles to diluted weighted average shares outstanding as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Basic weighted average common shares outstanding
75,460

 
76,539

 
75,450

 
76,479

Dilutive effect of stock options, restricted stock and performance share units
927

 
1,165

 
884

 
1,243

Diluted weighted average common shares outstanding
76,387

 
77,704

 
76,334

 
77,722



Options to purchase approximately 0.6 million and 0.3 million shares of common stock for the three months ended June 30, 2019 and 2018, respectively, and 0.6 million and 0.3 million shares of common stock for the six months ended June 30, 2019 and 2018, respectively, were not included in the computation of diluted EPS because the effect of their inclusion would have been antidilutive.

6.    Inventories

The components of inventories as of June 30, 2019 and December 31, 2018 were:
 
June 30,
2019
 
December 31,
2018
Raw materials and component parts
$
186,117

 
$
178,805

Work in process
28,480

 
37,495

Finished goods
86,409

 
63,695

Total inventories
$
301,006

 
$
279,995



Inventories are stated at the lower of cost or net realizable value. Cost, which includes material, labor and factory overhead, is determined on a FIFO basis.

7.    Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the six months ended June 30, 2019, by reportable business segment, were as follows:
 
FMT
 
HST
 
FSDP
 
IDEX
Balance at December 31, 2018
$
581,041

 
$
745,357

 
$
371,557

 
$
1,697,955

Foreign currency translation
(610
)
 
637

 
(833
)
 
(806
)
Acquisition adjustments

 
183

 

 
183

Balance at June 30, 2019
$
580,431

 
$
746,177

 
$
370,724

 
$
1,697,332



ASC 350, Goodwill and Other Intangible Assets, requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. In the first six months of 2019, there were no events or circumstances that would have required an interim impairment test. Annually, on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. Based on the results of our annual impairment test at October 31, 2018, all reporting units had fair values in excess of their carrying values.

 

14

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at June 30, 2019 and December 31, 2018:
 
At June 30, 2019
 
 
 
At December 31, 2018
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
 
Weighted
Average
Life
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Amortized intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Patents
$
6,555

 
$
(4,986
)
 
$
1,569

 
12
 
$
6,468

 
$
(4,693
)
 
$
1,775

Trade names
115,890

 
(60,962
)
 
54,928

 
16
 
115,899

 
(57,227
)
 
58,672

Customer relationships
253,470

 
(92,394
)
 
161,076

 
14
 
256,202

 
(85,652
)
 
170,550

Unpatented technology
97,494

 
(40,384
)
 
57,110

 
12
 
96,922

 
(35,685
)
 
61,237

Other
700

 
(542
)
 
158

 
10
 
700

 
(507
)
 
193

Total amortized intangible assets
474,109

 
(199,268
)
 
274,841

 
 
 
476,191

 
(183,764
)
 
292,427

Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Banjo trade name
62,100

 

 
62,100

 
 
 
62,100

 

 
62,100

Akron Brass trade name
28,800

 

 
28,800

 
 
 
28,800

 

 
28,800

Total intangible assets
$
565,009

 
$
(199,268
)
 
$
365,741

 
 
 
$
567,091

 
$
(183,764
)
 
$
383,327



The Banjo trade name and the Akron Brass trade name are indefinite-lived intangible assets which are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the assets might be impaired. In the first six months of 2019, there were no events or circumstances that would have required an interim impairment test. The Company uses the relief-from-royalty method, a form of the income approach, to determine the fair value of these trade names. The relief-from-royalty method is dependent on a number of significant management assumptions, including estimates of revenues, royalty rates and discount rates.

Amortization of intangible assets was $9.0 million and $18.0 million for the three and six months ended June 30, 2019, respectively. Amortization of intangible assets was $9.8 million and $20.7 million for the three and six months ended June 30, 2018, respectively. Based on the intangible asset balances as of June 30, 2019, amortization expense is expected to approximate $18.0 million for the remaining six months of 2019, $35.3 million in 2020, $34.1 million in 2021, $32.3 million in 2022 and $29.2 million in 2023.


15

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

8.    Accrued Expenses

The components of accrued expenses as of June 30, 2019 and December 31, 2018 were:
 
June 30,
2019
 
December 31,
2018
Payroll and related items
$
68,586

 
$
78,944

Management incentive compensation
10,441

 
25,321

Income taxes payable
12,500

 
23,844

Insurance
9,513

 
10,422

Warranty
5,284

 
5,303

Deferred revenue
11,861

 
8,055

Lease liability
12,973

 

Restructuring
3,903

 
6,170

Liability for uncertain tax positions
830

 
980

Accrued interest
1,569

 
1,759

Other
25,378

 
26,738

Total accrued expenses
$
162,838

 
$
187,536



9.    Other Noncurrent Liabilities

The components of other noncurrent liabilities as of June 30, 2019 and December 31, 2018 were:
 
June 30,
2019
 
December 31,
2018
Pension and retiree medical obligations
$
76,228

 
$
80,667

Transition tax payable
17,127

 
17,127

Liability for uncertain tax positions
3,255

 
3,183

Deferred revenue
2,512

 
3,027

Liability for construction of new leased facility

 
11,616

Lease liability
54,619

 

Contingent consideration for acquisition
3,375

 
3,375

Other
20,565

 
19,219

Total other noncurrent liabilities
$
177,681

 
$
138,214




16

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

10.    Borrowings

Borrowings at June 30, 2019 and December 31, 2018 consisted of the following: 
 
June 30,
2019
 
December 31,
2018
Revolving Facility
$

 
$

4.50% Senior Notes, due December 2020
300,000

 
300,000

4.20% Senior Notes, due December 2021
350,000

 
350,000

3.20% Senior Notes, due June 2023
100,000

 
100,000

3.37% Senior Notes, due June 2025
100,000

 
100,000

Other borrowings
824

 
1,078

Total borrowings
850,824

 
851,078

Less current portion
452

 
483

Less deferred debt issuance costs
1,288

 
1,593

Less unaccreted debt discount
529

 
667

Total long-term borrowings
$
848,555

 
$
848,335



On June 13, 2016, the Company completed a private placement of a $100 million aggregate principal amount of 3.20% Senior Notes due June 13, 2023 and a $100 million aggregate principal amount of 3.37% Senior Notes due June 13, 2025 (collectively, the “Notes”) pursuant to a Note Purchase Agreement dated June 13, 2016 (the “Purchase Agreement”). Each series of Notes bears interest at the stated amount per annum, which is payable semi-annually in arrears on each June 13th and December 13th. The Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other unsecured, unsubordinated debt. The Company may at any time prepay all, or any portion of the Notes, provided that such portion is greater than 5% of the aggregate principal amount of the Notes then outstanding. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole amount. In addition, the Company may repurchase the Notes by making an offer to all holders of the Notes, subject to certain conditions.

The Purchase Agreement contains certain covenants that restrict the Company’s ability to, among other things, transfer or sell assets, incur indebtedness, create liens, transact with affiliates and engage in certain mergers or consolidations or other change of control transactions. In addition, the Company must comply with a leverage ratio and interest coverage ratio, as further described below, and the Purchase Agreement also limits the outstanding principal amount of priority debt that may be incurred by the Company to 15% of consolidated assets. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all of the outstanding Notes will become due and payable immediately without further action or notice. In the case of a payment event of default, any holder of the Notes affected thereby may declare all of the Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the Notes may declare all of the Notes to be due and payable immediately.

On May 31, 2019, the Company entered into a credit agreement (the “Credit Agreement”) along with certain of its subsidiaries, as borrowers (the “Borrowers”), Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, with other agents party thereto. The Credit Agreement replaces the Company’s existing five-year, $700 million credit agreement, dated as of June 23, 2015, which was due to expire in June 2020.

Terms and fees of the 2019 Credit Agreement are essentially the same as the 2015 credit agreement except for certain fees and interest rate pricing that are more favorable to the Company.

The Credit Agreement consists of a revolving credit facility (the “Revolving Facility”) in an aggregate principal amount of $800 million with a final maturity date of May 30, 2024. The maturity date may be extended under certain conditions for an additional one-year term. Up to $75 million of the Revolving Facility under the Credit Agreement is available for the issuance of letters of credit. Additionally, up to $50 million of the Revolving Facility is available to the Company for swing line loans, available on a same-day basis.


17

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Proceeds of the Revolving Facility are available for use by the Borrowers for working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments pursuant to such increases may not exceed $400 million. The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement.

Borrowings under the Credit Agreement bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the better of the Company’s senior, unsecured, long-term debt rating or the Company’s applicable leverage ratio. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the last day of the applicable interest period selected, or every three months from the effective date of such interest period for interest periods exceeding three months.

Voluntary prepayments of any loans and voluntary reductions of the unutilized portion of the commitments under the Credit Agreement are permissible without penalty, subject to break funding payments and minimum notice and minimum reduction amount requirements.

The Credit Agreement contains affirmative and negative covenants usual and customary for such senior unsecured credit agreements, including an interest coverage ratio test and a leverage ratio test, in each case tested quarterly and, in the case of the leverage ratio, with an option to increase the ratio for 12 months in connection with certain acquisitions. The negative covenants include restrictions on the Company on granting liens, entering into transactions resulting in fundamental changes (such as mergers or sales of all or substantially all of the assets of the Company), making certain subsidiary dividends or distributions, engaging in materially different lines of businesses and allowing subsidiaries to incur certain additional debt.

The Credit Agreement also contains customary events of default (subject to grace periods, as appropriate).

At June 30, 2019, there was no balance outstanding under the Revolving Facility and $9.1 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility at June 30, 2019 of approximately $790.9 million.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and the Notes, a minimum interest coverage ratio of 3.00 to 1 and a maximum leverage ratio of 3.50 to 1, which is the ratio of the Company’s consolidated total debt to its consolidated EBITDA. In the case of the leverage ratio, there is an option to increase the ratio to 4.00 for 12 months in connection with certain acquisitions. At June 30, 2019, the Company was in compliance with both of these financial covenants. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes; however, both are subject to cross-default provisions.

11.    Derivative Instruments

The Company enters into cash flow hedges from time to time to reduce the exposure to variability in certain expected future cash flows. The types of cash flow hedges the Company enters into include foreign currency exchange contracts designed to minimize the earnings impact on certain intercompany loans as well as interest rate exchange agreements designed to reduce the impact of interest rate changes on future interest expense that effectively convert a portion of floating-rate debt to fixed-rate debt.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders’ equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized in net income during the period of change. See Note 15 for the amount of loss reclassified into net income for interest rate contracts for the three and six months ended June 30, 2019 and 2018. As of June 30, 2019, the Company did not have any interest rate contracts outstanding.

In 2010 and 2011, the Company entered into two separate forward starting interest rate exchange agreements in anticipation of the issuance of the 4.2% Senior Notes and the 4.5% Senior Notes. The Company cash settled these two interest rate contracts in 2010 and 2011 for a total of $68.9 million, which is being amortized into interest expense over the 10 year terms of the respective debt instruments. Approximately $6.2 million of the pre-tax amount included in Accumulated other comprehensive income (loss)

18

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

in shareholders’ equity at June 30, 2019 will be recognized in net income over the next 12 months as the underlying hedged transactions are realized.

At March 31, 2018, the Company had outstanding foreign currency exchange contracts with a combined notional value of 180 million that were not designated as hedges for accounting purposes and, as a result, the change in the fair value of these foreign currency exchange contracts and the corresponding foreign currency gain or loss on the revaluation of the intercompany loans were both recorded through earnings within Other (income) expense - net in the Condensed Consolidated Statements of Operations each period as incurred.

During the three and six months ended June 30, 2018, the Company recorded a loss of $0.3 million and a gain of $0.9 million, respectively, within Other (income) expense - net in the Condensed Consolidated Statements of Operations related to these foreign currency exchange contracts. During the three and six months ended June 30, 2018, the Company recorded a foreign currency transaction gain of $0.3 million and a foreign currency transaction loss of $0.9 million, respectively, within Other (income) expense - net in the Condensed Consolidated Statements of Operations related to these intercompany loans. For the six months ended June 30, 2018, the Company received $6.6 million in settlement of the foreign currency exchange contracts.
In April 2018, the Company settled its outstanding foreign currency exchange contracts in conjunction with its repayment of the underlying intercompany loans and did not extend these foreign currency exchange contracts. Along with the repayment of the intercompany loans, the Company was required to make a capital contribution to one of its subsidiaries, which resulted in a $2.2 million stamp duty in Switzerland which was recorded within Selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.

Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date.

12.    Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to the valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheets at June 30, 2019 and December 31, 2018:
 
Basis of Fair Value Measurements
 
Balance at 
 June 30, 2019
 
Level 1
 
Level 2
 
Level 3
Available for sale securities
$
9,429

 
$
9,429

 
$

 
$

Contingent consideration
3,375

 

 

 
3,375

 
Basis of Fair Value Measurements
 
Balance at 
 December 31, 2018
 
Level 1
 
Level 2
 
Level 3
Available for sale securities
$
7,598

 
$
7,598

 
$

 
$

Contingent consideration
3,375

 

 

 
3,375




19

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

There were no transfers of assets or liabilities between Level 1 and Level 2 during the three and six months ended June 30, 2019 or the year ended December 31, 2018.

The Company utilized a Monte Carlo Simulation to determine the fair value of the contingent consideration associated with the acquisition of FLI as of the acquisition date. The $3.4 million represents management’s best estimate of the liability, based on a range of outcomes of FLI’s two-year operating results, from August 1, 2018 to July 31, 2020, and is expected to be paid during the third quarter of 2020. As of June 30, 2019, the $3.4 million of contingent consideration is included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets.
 
The carrying values of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair values because of the short term nature of these instruments. At June 30, 2019, the fair value of the outstanding indebtedness under our 3.2% Senior Notes, 3.37% Senior Notes, 4.5% Senior Notes, 4.2% Senior Notes and other borrowings based on quoted market prices and current market rates for debt with similar credit risk and maturity was approximately $875.8 million compared to the carrying value of $850.3 million. At December 31, 2018, the fair value of the outstanding indebtedness under our 3.2% Senior Notes, 3.37% Senior Notes, 4.5% Senior Notes, 4.2% Senior Notes and other borrowings based on quoted market prices and current market rates for debt with similar credit risk and maturity was approximately $851.5 million compared to the carrying value of $850.4 million. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to ours.

13.    Leases

The Company leases certain office facilities, warehouses, manufacturing plants, equipment (which includes both office and plant equipment) and vehicles under operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

Certain leases include one or more options to renew. The exercise of lease renewal options is at the Company’s sole discretion. There are currently no renewal periods included in any of the leases’ respective lease terms as they are not reasonably certain of being exercised. The Company does not have any material purchase options.

Certain of our lease agreements have rental payments that are adjusted periodically for inflation or that are based on usage. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information related to leases as of June 30, 2019 was as follows:
 
Balance Sheet Caption
June 30, 
 2019
Operating leases:
 
 
Building right-of-use assets - net
Other noncurrent assets
$
59,226

Equipment right-of-use assets - net
Other noncurrent assets
6,636

Total right-of-use assets - net
 
$
65,862

Operating leases:
 
 
Current lease liabilities
Accrued expenses
$
12,973

Noncurrent lease liabilities
Other noncurrent liabilities
54,619

Total lease liabilities
 
$
67,592




20

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

As part of the adoption of the new lease standard, the Company derecognized its liability for the construction of a new leased facility that was recorded in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets and recorded it as a right of use asset in Other noncurrent assets on the Condensed Consolidated Balance Sheets with a corresponding lease liability in Accrued expenses and Other noncurrent liabilities on the Condensed Consolidated Balance Sheets.

The components of lease cost for the three and six months ended June 30, 2019 were as follows:
 
Three Months Ended 
 June 30, 2019
 
Six Months Ended 
 June 30, 2019
Operating lease cost (1)
$
6,195

 
$
11,570

Variable lease cost
625

 
1,218

Total lease expense
$
6,820

 
$
12,788


(1) Includes short-term leases, which are immaterial.

Supplemental cash flow information related to leases for the six months ended June 30, 2019 was as follows:
 
Six Months Ended 
 June 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
$
6,071

Right-of-use assets obtained in exchange for new operating lease liabilities
4,180



Other supplemental information related to leases as of June 30, 2019 was as follows:
Lease Term and Discount Rate
June 30, 
 2019
Weighted-average remaining lease term (years):
 
Operating leases - building and equipment
8.32

Operating leases - vehicles
2.18

Weighted-average discount rate:
 
Operating leases - building and equipment
4.06
%
Operating leases - vehicles
3.28
%


The Company uses the implicit rate to determine the present value of the lease payments. If the implicit rate is not defined in the lease, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company used either the implicit rate or the incremental borrowing rate based on the information available at the transition date to determine the present value of the lease payments as of January 1, 2019.

21

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)


Total lease liabilities at June 30, 2019 have scheduled maturities as follows:
Maturity of Lease Liabilities
Operating Leases (1)
2019 (excluding the six months ended June 30, 2019)
$
7,620

2020
13,609

2021
11,609

2022
8,820

2023
6,857

Thereafter
30,837

Total lease payments
79,352

Less: Imputed interest
(11,760
)
Present value of lease liabilities
$
67,592


(1) Excludes $25.2 million of legally binding minimum lease payments for leases signed but not yet commenced.

Total lease liabilities at December 31, 2018 had scheduled maturities as follows:
Maturity of Lease Liabilities
Operating Leases
2019
$
17,509

2020
13,162

2021
10,516

2022
7,979

2023
6,535

Thereafter
29,658

Total lease payments
$
85,359



14.    Restructuring

During the year ended December 31, 2018 and the three months ended June 30, 2019, the Company recorded accruals for restructuring costs incurred as part of restructuring initiatives that supported the implementation of key strategic efforts designed to facilitate long-term, sustainable growth through cost reduction actions, primarily consisting of employee reductions and facility rationalization. The restructuring costs included severance benefits and exit costs which were included in Restructuring expenses in the Condensed Consolidated Statements of Operations. Severance costs primarily consisted of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs and employer tax liabilities, while exit costs primarily consisted of asset disposals or impairments and lease exit and contract termination costs.
Pre-tax restructuring expenses by segment for the three and six months ended June 30, 2019 were as follows:
 
Severance Costs
 
Exit Costs
 
Total
Fluid & Metering Technologies
$
930

 
$

 
$
930

Health & Science Technologies
46

 
284

 
330

Fire & Safety/Diversified Products
819

 

 
819

Corporate/Other
47

 

 
47

Total restructuring costs
$
1,842

 
$
284

 
$
2,126

 
 
 
 
 
 


22

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Restructuring accruals of $3.9 million and $6.2 million at June 30, 2019 and December 31, 2018, respectively, are recorded in Accrued expenses on the Condensed Consolidated Balance Sheets. Severance benefits are expected to be paid by the end of the year using cash from operations. The changes in the restructuring accrual for the six months ended June 30, 2019 are as follows:
 
Restructuring
Balance at January 1, 2019
$
6,170

Restructuring expenses
2,126

Payments, utilization and other
(4,393
)
Balance at June 30, 2019
$
3,903



15.    Other Comprehensive Income (Loss)

The components of Other comprehensive income (loss) are as follows:
 
Three Months Ended 
 June 30, 2019
 
Three Months Ended 
 June 30, 2018
 
Pre-tax
 
Tax
 
Net of tax
 
Pre-tax
 
Tax
 
Net of tax
Cumulative translation adjustment
$
2,628

 
$

 
$
2,628

 
$
(62,645
)
 
$

 
$
(62,645
)
Pension and other postretirement adjustments
1,691

 
(435
)
 
1,256

 
1,753

 
(457
)
 
1,296

Reclassification adjustments for derivatives
1,583

 
(359
)
 
1,224

 
1,627

 
(368
)
 
1,259

Total other comprehensive income (loss)
$
5,902

 
$
(794
)
 
$
5,108

 
$
(59,265
)
 
$
(825
)
 
$
(60,090
)
 
Six Months Ended 
 June 30, 2019
 
Six Months Ended 
 June 30, 2018
 
Pre-tax
 
Tax
 
Net of tax
 
Pre-tax
 
Tax
 
Net of tax
Cumulative translation adjustment
$
(653
)
 
$

 
$
(653
)
 
$
(35,067
)
 
$

 
$
(35,067
)
Pension and other postretirement adjustments
3,391

 
(873
)
 
2,518

 
3,671

 
(962
)
 
2,709

Reclassification adjustments for derivatives
3,171

 
(720
)
 
2,451

 
3,259

 
(739
)
 
2,520

Total other comprehensive income (loss)
$
5,909

 
$
(1,593
)
 
$
4,316

 
$
(28,137
)
 
$
(1,701
)
 
$
(29,838
)


The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss) to net income during the three and six months ended June 30, 2019 and 2018:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
 
2019
 
2018
 
2019
 
2018
Income Statement Caption
Pension and other postretirement plans:
 
 
 
 
 
 
 
 
Amortization of service cost
$
1,691

 
$
1,753

 
$
3,391

 
$
3,671

Other (income) expense - net
Total before tax
1,691

 
1,753

 
3,391

 
3,671

 
Provision for income taxes
(435
)
 
(457
)
 
(873
)
 
(962
)
 
Total net of tax
$
1,256

 
$
1,296

 
$
2,518

 
$
2,709

 
Derivatives:
 
 
 
 
 
 
 
 
Reclassification adjustments
$
1,583

 
$
1,627

 
$
3,171

 
$
3,259

Interest expense
Total before tax
1,583

 
1,627

 
3,171

 
3,259

 
Provision for income taxes
(359
)
 
(368
)
 
(720
)
 
(739
)
 
Total net of tax
$
1,224

 
$
1,259

 
$
2,451

 
$
2,520

 


The Company recognizes the service cost component in both Selling, general and administrative expenses and Cost of sales in the Condensed Consolidated Statements of Operations depending on the functional area of the underlying employees included in the plans.

23

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)


16.    Common and Preferred Stock

On December 1, 2015, the Company’s Board of Directors approved an increase of $300.0 million in the authorized level of repurchases of common stock. This followed the prior Board of Directors approved repurchase authorization of $400.0 million that was announced by the Company on November 6, 2014. These authorizations have no expiration date. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Facility. During the six months ended June 30, 2019, the Company repurchased a total of 389 thousand shares at a cost of $54.7 million. During the six months ended June 30, 2018, the Company repurchased a total of 147 thousand shares at a cost of $20.5 million, of which $1.0 million was settled in July 2018. As of June 30, 2019, the amount of share repurchase authorization remaining was $322.3 million.

At June 30, 2019 and December 31, 2018, the Company had 150 million shares of authorized common stock, with a par value of $.01 per share, and 5 million shares of authorized preferred stock, with a par value of $.01 per share. No preferred stock was outstanding at June 30, 2019 or December 31, 2018.

17.    Share-Based Compensation

The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Board of Directors based on their recommendation from the Compensation Committee.

Stock Options

Stock options generally vest ratably over four years. Weighted average option fair values and assumptions for the periods specified are disclosed below. The fair value of each option grant was estimated on the date of the grant using the Binomial lattice option pricing model.
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Weighted average fair value of grants
$34.82
 
$37.22
 
$35.16
 
$38.09
Dividend yield
1.18%
 
1.24%
 
1.18%
 
1.07%
Volatility
23.31%
 
28.01%
 
24.78%
 
28.49%
Risk-free interest rate
2.37% - 2.62%
 
2.28% - 3.11%
 
2.53% - 3.04%
 
2.01% - 3.17%
Expected life (in years)
5.86
 
5.82
 
5.87
 
5.83


Total compensation cost for stock options is as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Cost of goods sold
$
90

 
$
91

 
$
282

 
$
297

Selling, general and administrative expenses
1,986

 
1,881

 
4,526

 
4,405

Total expense before income taxes
2,076

 
1,972

 
4,808

 
4,702

Income tax benefit
(284
)
 
(364
)
 
(652
)
 
(834
)
Total expense after income taxes
$
1,792

 
$
1,608

 
$
4,156

 
$
3,868



24

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)


A summary of the Company’s stock option activity as of June 30, 2019 and changes during the six months ended June 30, 2019 are presented in the following table:
Stock Options
Shares
 
Weighted
Average
Price
 
Weighted-Average
Remaining
Contractual Term
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2019
1,714,003

 
$
85.08

 
6.70
 
$
74,191,783

Granted
334,430

 
144.89

 
 
 
 
Exercised
(298,167
)
 
69.54

 
 
 
 
Forfeited
(61,098
)
 
112.34

 
 
 
 
Outstanding at June 30, 2019
1,689,168

 
$
98.68

 
7.06
 
$
124,043,143

Vested and expected to vest as of June 30, 2019
1,587,297

 
$
95.88

 
6.88
 
$
121,043,268

Exercisable at June 30, 2019
860,924

 
$
75.87

 
5.64
 
$
82,885,109



Restricted Stock

Restricted stock awards generally cliff vest after three years for employees and non-employee directors. Unvested restricted stock carries dividend and voting rights and the sale of the shares is restricted prior to the date of vesting. A summary of the Company’s restricted stock activity as of June 30, 2019 and changes during the six months ended June 30, 2019 are presented as follows:
Restricted Stock
Shares
 
Weighted-Average
Grant Date Fair
Value
Unvested at January 1, 2019
148,041

 
$
101.50

Granted
40,890

 
146.25

Vested
(35,552
)
 
74.88

Forfeited
(8,400
)
 
125.11

Unvested at June 30, 2019
144,979

 
$
119.70



Dividends are paid on restricted stock awards whose fair value is equal to the market price of the Company’s stock at the date of the grant.

Total compensation cost for restricted shares is as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Cost of goods sold
$
64

 
$
83

 
$
202

 
$
239

Selling, general and administrative expenses
1,037

 
964

 
2,325

 
2,253

Total expense before income taxes
1,101

 
1,047

 
2,527

 
2,492

Income tax benefit
(205
)
 
(186
)
 
(480
)
 
(443
)
Total expense after income taxes
$
896

 
$
861

 
$
2,047

 
$
2,049




25

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Cash-Settled Restricted Stock

The Company also maintains a cash-settled share based compensation plan for certain employees. Cash-settled restricted stock awards generally cliff vest after three years. Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company’s stock on the last day of the quarter. A summary of the Company’s unvested cash-settled restricted stock activity as of June 30, 2019 and changes during the six months ended June 30, 2019 are presented in the following table:
Cash-Settled Restricted Stock
Shares
 
Weighted-Average
Fair Value
Unvested at January 1, 2019
88,225

 
$
126.26

Granted
25,585

 
145.18

Vested
(27,900
)
 
144.12

Forfeited
(4,360
)
 
155.18

Unvested at June 30, 2019
81,550

 
$
172.14



Dividend equivalents are paid on certain cash-settled restricted stock awards. Total compensation cost for cash-settled restricted stock is as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Cost of goods sold
$
336

 
$
102

 
$
836

 
$
515

Selling, general and administrative expenses
1,167

 
508

 
2,697

 
1,712

Total expense before income taxes
1,503

 
610

 
3,533

 
2,227

Income tax benefit
(159
)
 
(51
)
 
(346
)
 
(210
)
Total expense after income taxes
$
1,344

 
$
559

 
$
3,187

 
$
2,017



Performance Share Units

Weighted average performance share unit fair values and assumptions for the period specified are disclosed below. The performance share units are market condition awards and have been assessed at fair value on the date of grant using a Monte Carlo simulation model.
 
Six Months Ended 
 June 30,
 
2019
 
2018
Weighted average fair value of grants
$207.26
 
$216.59
Dividend yield
%
 
%
Volatility
19.11%
 
17.42%
Risk-free interest rate
2.49%
 
2.40%
Expected life (in years)
2.83
 
2.85



26

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

A summary of the Company’s performance share unit activity as of June 30, 2019 and changes during the six months ended June 30, 2019 are presented in the following table:
Performance Share Units
Shares
 
Weighted-Average
Grant Date Fair
Value
Unvested at January 1, 2019
111,155

 
$
142.42

Granted
56,860

 
207.26

Vested

 

Forfeited
(9,850
)
 
163.68

Unvested at June 30, 2019
158,165

 
$
179.06



On December 31, 2018, 69,995 performance share units vested. Based on the Company’s relative total shareholder return rank during the three year period ended December 31, 2018, the Company achieved a 250% payout factor and issued 174,994 common shares in February 2019.

Total compensation cost for performance share units is as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Cost of goods sold
$

 
$

 
$

 
$

Selling, general and administrative expenses
2,173

 
1,971

 
3,545

 
3,831

Total expense before income taxes
2,173

 
1,971

 
3,545

 
3,831

Income tax benefit
(203
)
 
(388
)
 
(251
)
 
(705
)
Total expense after income taxes
$
1,970

 
$
1,583

 
$
3,294

 
$
3,126



The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of stock compensation cost within the Condensed Consolidated Statements of Operations is consistent with classification of cash compensation for the same employees.

As of June 30, 2019, there was $17.3 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.5 years, $2.0 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 1.2 years, $5.4 million of total unrecognized compensation cost related to cash-settled restricted shares that is expected to be recognized over a weighted-average period of 1.1 years and $12.6 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.1 years.


27

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

18.    Retirement Benefits

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans and other postretirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.
 
Pension Benefits
 
Three Months Ended June 30,
 
2019
 
2018
 
U.S.
 
Non-U.S.
 
U.S.
 
Non-U.S.
Service cost
$
209

 
$
460

 
$
255

 
$
527

Interest cost
764

 
361

 
653

 
351

Expected return on plan assets
(801
)
 
(262
)
 
(983
)
 
(282
)
Net amortization
486

 
280

 
685

 
322

Net periodic benefit cost
$
658

 
$
839

 
$
610

 
$
918

 
Pension Benefits
 
Six Months Ended June 30,
 
2019
 
2018
 
U.S.
 
Non-U.S.
 
U.S.
 
Non-U.S.
Service cost
$
417

 
$
924

 
$
509

 
$
1,072

Interest cost
1,528

 
726

 
1,306

 
712

Expected return on plan assets
(1,602
)
 
(526
)
 
(1,966
)
 
(572
)
Net amortization
973

 
564

 
1,370

 
652

Net periodic benefit cost
$
1,316

 
$
1,688

 
$
1,219

 
$
1,864


 
Other Postretirement Benefits
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Service cost
$
140

 
$
167

 
$
280

 
$
335

Interest cost
212

 
203

 
424

 
406

Net amortization
(158
)
 
(184
)
 
(317
)
 
(368
)
Net periodic benefit cost
$
194

 
$
186

 
$
387

 
$
373



The Company previously disclosed in its financial statements for the year ended December 31, 2018, that it expected to contribute approximately $0.6 million to its defined benefit plans and $1.1 million to its other postretirement benefit plans in 2019. During the first six months of 2019, the Company contributed a total of $0.1 million to fund these plans.

19.    Legal Proceedings

The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings arising in the ordinary course of business. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company’s business, financial condition, results of operations or cash flows.


28

Table of Contents

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

20.    Income Taxes

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to $31.4 million for the three months ended June 30, 2019 from $29.6 million during the same period in 2018. The effective tax rate of 21.7% for the three months ended June 30, 2019 was flat compared to the same period in 2018.

The provision for income taxes decreased to $58.2 million for the six months ended June 30, 2019 from $60.8 million during the same period in 2018. The effective tax rate decreased to 20.7% for the six months ended June 30, 2019 compared to 22.8% during the same period in 2018 due to an increase in foreign tax credits as a result of U.S. Treasury proposed regulations issued related to Global Intangible Low-Taxed Income (“GILTI”), discrete income tax expense in first quarter 2018 related to IRS Revenue Procedure 2018-17 and IRS Notice 2018-26 as well as the mix of global pre-tax income among jurisdictions.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitation, it is reasonably possible that the Company’s gross unrecognized tax benefits balance may change within the next twelve months by a range of zero to $0.8 million.

21.    Subsequent Events

On July 18, 2019, the Company acquired Velcora Holding AB (“Velcora”) and its Roplan and Steridose businesses for cash consideration of $87.3 million and $49.9 million of assumed debt. Roplan is a global manufacturer of custom mechanical and shaft seals for a variety of end markets including food and beverage, marine, chemical, wastewater and water treatment. Steridose develops engineered hygienic mixers and valves for the global biopharmaceutical industry. Both companies are headquartered in Sweden, with operations in China, the United Kingdom and the United States. Roplan and Steridose have annual revenues of approximately $40.0 million and will operate in the Health & Science Technologies segment.



29

Table of Contents


Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statement Under the Private Securities Litigation Reform Act

This quarterly report on Form 10-Q, including the “Overview and Outlook” and “Liquidity and Capital Resources” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company’s results, particularly in light of the low levels of order backlogs it typically maintains; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

Overview and Outlook

IDEX is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business and by the relationship of the U.S. Dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are important factors that influence the demand for IDEX’s products.

The Company has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products. Within our three reportable segments, the Company maintains 13 platforms, where we focus on organic growth and strategic acquisitions. Each of our 13 platforms is also a reporting unit that we annually test goodwill for impairment.

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agriculture and energy industries. The Fluid & Metering Technologies segment contains the Energy platform (comprised of Corken, Liquid Controls, SAMPI and Toptech), the Valves platform (comprised of Alfa Valvole, Richter and Aegis), the Water platform (comprised of Pulsafeeder, OBL, Knight, ADS, Trebor and iPEK), the Pumps platform (comprised of Viking and Warren Rupp) and the Agriculture platform (comprised of Banjo).

The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded sealing components, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications. The Health & Science Technologies segment contains the Scientific Fluidics & Optics platform (comprised of Eastern Plastics, Rheodyne, Sapphire Engineering, Upchurch Scientific, ERC, CiDRA Precision Services, thinXXS, CVI Melles Griot, Semrock, Advanced Thin Films and FLI), the Sealing Solutions platform (comprised of Precision Polymer Engineering, FTL Seals Technology, Novotema and SFC Koenig), the Gast platform, the Micropump platform and the Material Processing Technologies platform (comprised of Quadro, Fitzpatrick, Microfluidics and Matcon).

30

Table of Contents



The Fire & Safety/Diversified Products segment designs, produces and develops firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world. The Fire & Safety/Diversified Products segment is comprised of the Fire & Safety platform (comprised of Class 1, Hale, Akron Brass, AWG Fittings, Godiva, Dinglee, Hurst Jaws of Life, Lukas and Vetter), the BAND-IT platform and the Dispensing platform.

Management’s primary measurements of segment performance are sales, operating income and operating margin. In addition, due to the highly acquisitive nature of the Company, the determination of operating income includes amortization of acquired intangible assets and as a result, management reviews depreciation and amortization as a percentage of sales. These measures are monitored by management and significant changes in operating results versus current trends in end markets and variances from forecasts are analyzed with segment management.

This report references organic sales, a non-GAAP measure, that refers to sales from continuing operations calculated according to generally accepted accounting principles in the United States of America (“U.S. GAAP”) but excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first twelve months of ownership or divestiture. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers.

EBITDA means earnings before interest, income taxes, depreciation and amortization. Given the acquisitive nature of the Company, which results in a higher level of amortization expense from recently acquired businesses, management uses EBITDA as an internal operating metric to provide another representation of the businesses’ performance across our three segments and for enterprise valuation purposes. Management believes that EBITDA is useful to investors as an indicator of the strength and performance of the Company and a way to evaluate and compare operating performance and value companies within our industry. Management believes that EBITDA margin is useful for the same reason as EBITDA. EBITDA is also used to calculate certain financial covenants, as discussed in Note 10 in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, “Financial Statements.”

Organic sales have been reconciled to net sales and EBITDA has been reconciled to net income in Item 2 under the heading “Non-GAAP Disclosures.” The reconciliation of segment EBITDA to net income was performed on a consolidated basis due to the fact that we do not allocate consolidated interest expense or the consolidated provision for income taxes to our segments.

Management uses Adjusted operating income, Adjusted net income, Adjusted EBITDA and Adjusted EPS as metrics by which to measure performance of the Company since they exclude items that are not reflective of ongoing operations, such as restructuring expenses.

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

Some of our key financial results for the three months ended June 30, 2019 when compared to the same period in the prior year are as follows:

Sales of $642.1 million increased 1%; organic sales (which excludes acquisitions and foreign currency translation) were up 3%.
Operating income of $155.3 million increased 5%. Adjusted operating income of $157.4 million, adjusted for $2.1 million of restructuring expenses in the second quarter of 2019, increased 5%.
Net income of $113.2 million increased 6%. Adjusted net income of $114.8 million, adjusted for $1.6 million of restructuring expenses, net of tax benefit, in the second quarter of 2019, increased 6%.
EBITDA of $174.8 million was 27% of sales and covered interest expense by almost 16 times. Adjusted EBITDA of $177.0 million was 28% of sales and covered interest expense by over 16 times.

31

Table of Contents


Diluted EPS of $1.48 increased 10 cents, or 7%. Adjusted EPS of $1.50 increased 10 cents, or 7%.

Some of our key financial results for the six months ended June 30, 2019 when compared to the same period in the prior year are as follows:

Sales of $1,264.3 million increased 1%; organic sales (which excludes acquisitions and foreign currency translation) were up 3%.
Operating income of $303.1 million increased 7%. Adjusted operating income of $305.2 million, adjusted for $2.1 million of restructuring expenses during 2019, increased 6%.
Net income of $223.5 million increased 8%. Adjusted net income of $225.0 million, adjusted for $1.6 million of restructuring expenses, net of tax benefit, during 2019, increased 8%.
EBITDA of $341.4 million was 27% of sales and covered interest expense by almost 16 times. Adjusted EBITDA of $343.5 million was 27% of sales and covered interest expense by almost 16 times.
Diluted EPS of $2.92 increased 27 cents, or 10%. Adjusted EPS of $2.94 increased 25 cents, or 9%.

Given the Company’s current outlook, we are projecting third quarter 2019 EPS in the range of $1.45 to $1.47 with full year 2019 EPS of $5.78 to $5.85. We are also projecting third quarter organic revenue growth of approximately 3% with full year organic revenue growth of 3% to 4%.

Results of Operations

The following is a discussion and analysis of our results of operations for the three and six months ended June 30, 2019 and 2018. Segment operating income and EBITDA exclude unallocated corporate operating expenses of $19.2 million and $21.8 million for the three months ended June 30, 2019 and 2018, respectively, and $37.8 million and $42.7 million for the six months ended June 30, 2019 and 2018, respectively.

Consolidated Results for the Three Months Ended June 30, 2019 Compared with the Same Period in 2018
(In thousands)
Three Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
642,099

 
$
634,360

Operating income
155,283

 
147,831

Operating margin
24.2
%
 
23.3
%

For the three months ended June 30, 2019, Fluid & Metering Technologies contributed 38% of sales, 42% of operating income and 41% of EBITDA; Health & Science Technologies contributed 36% of sales, 33% of operating income and 34% of EBITDA; and Fire & Safety/Diversified Products contributed 26% of sales, 25% of operating income and 25% of EBITDA. These percentages are calculated on the basis of total segment (not total Company) sales, operating income and EBITDA.

Sales in the second quarter of 2019 were $642.1 million, which was a 1% increase compared to the same period in 2018. This increase reflects a 3% increase in organic sales, partially offset by a 2% unfavorable impact from foreign currency translation. Sales to customers outside the U.S. represented approximately 49% of total sales in the second quarter of 2019 compared to 51% during the same period in 2018.

Gross profit of $292.3 million in the second quarter of 2019 increased $5.0 million, or 2%, compared to the same period in 2018, while gross margin of 45.5% in the second quarter of 2019 increased 20 basis points from 45.3% during the same period in 2018. Both gross profit and margin increased compared to the prior year period primarily due to price, volume leverage and productivity initiatives, partially offset by higher engineering investments.

Selling, general and administrative expenses decreased to $134.9 million in the second quarter of 2019 from $137.5 million during the same period in 2018. The decrease is primarily due to lower amortization and variable compensation costs in 2019 as well as the stamp duty charge in the second quarter of 2018. Corporate costs decreased to $19.2 million in the second quarter of 2019 compared to $21.6 million during the same period in 2018, mainly due to the stamp duty charge in 2018. As a percentage of sales, selling, general and administrative expenses were 21.0% for the second quarter of 2019, down 70 basis points compared to 21.7% during the same period in 2018.


32

Table of Contents


The Company incurred $2.1 million of restructuring expenses in the second quarter of 2019 compared with $2.0 million during the same period in 2018. The restructuring expenses were part of initiatives that support the implementation of key strategic efforts designed to facilitate long-term, sustainable growth through cost reduction actions primarily consisting of employee reductions and facility rationalization.

Operating income of $155.3 million and operating margin of 24.2% in the second quarter of 2019 were up from the $147.8 million and 23.3%, respectively, recorded during the same period in 2018. The increase in operating margin is primarily due to gross margin expansion along with reduced selling, general and administrative expenses in 2019.

Other (income) expense - net increased to $0.4 million of income in the second quarter of 2019 compared to $0.1 million of income during the same period in 2018, primarily due to gains on pension-related investments and higher interest income in 2019.

Interest expense of $11.0 million in the second quarter of 2019 was essentially flat compared to the same period in 2018.

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to $31.4 million in the second quarter of 2019 compared to $29.6 million during the same period in 2018. The effective tax rate was 21.7% for the second quarter of 2019 which was flat compared to the same period in 2018.

Net income in the second quarter of 2019 of $113.2 million increased from $107.1 million during the same period in 2018. Diluted earnings per share in the second quarter of 2019 of $1.48 increased $0.10, or 7%, compared to the same period in 2018.

Fluid & Metering Technologies Segment
(In thousands)
Three Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
246,189

 
$
242,800

Operating income
74,146

 
71,228

Operating margin
30.1
%
 
29.3
%

Sales of $246.2 million increased $3.4 million, or 1%, in the second quarter of 2019 compared to the same period in 2018. This reflects a 3% increase in organic sales, partially offset by a 2% unfavorable impact from foreign currency translation. In the second quarter of 2019, sales were flat domestically and increased 3% internationally compared to the same period in 2018. Sales to customers outside the U.S. were approximately 43% of total segment sales in both the second quarters of 2019 and 2018.

Sales within our Pumps platform increased in the second quarter of 2019 compared to the same period in 2018 due to strength in LACT (lease automatic custody transfer) projects and strong OEM activity. Sales within our Valves platform increased in the second quarter of 2019 compared to the same period in 2018 as a result of strong demand within chemical end markets domestically and in Asia. Sales within our Water platform were flat compared to the same period in 2018 driven by strong Europe and Asia distribution offset by headwinds in U.S. sales. Sales within our Energy platform were essentially flat compared to the same period in 2018. Sales within our Agriculture platform decreased in the second quarter of 2019 compared to the same period in 2018 due to decreased demand across both the agriculture and industrial OEM markets.

Operating income of $74.1 million and operating margin of 30.1% in the second quarter of 2019 were higher than the $71.2 million and 29.3%, respectively, recorded during the same period in 2018, primarily due to higher volume, price and productivity initiatives, partially offset by higher engineering investments.

Health & Science Technologies Segment
(In thousands)
Three Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
232,253

 
$
227,403

Operating income
56,763

 
52,569

Operating margin
24.4
%
 
23.1
%


33

Table of Contents


Sales of $232.3 million increased $4.9 million, or 2%, in the second quarter of 2019 compared to the same period in 2018. This reflects a 3% increase in organic sales and a 1% increase from acquisitions (FLI - July 2018), partially offset by a 2% unfavorable impact from foreign currency translation. In the second quarter of 2019, sales increased 9% domestically and decreased 3% internationally compared to the same period in 2018. Sales to customers outside the U.S. were approximately 54% of total segment sales in the second quarter of 2019 compared to 57% during the same period in 2018.

Sales within our Scientific Fluidics & Optics platform increased in the second quarter of 2019 compared to the same period in 2018 due to new products, market share wins, strong demand in our primary end markets, including analytical instrumentation, IVD and biotechnology as well as the FLI acquisition. Sales within our Gast platform increased in the second quarter of 2019 compared to the same period in 2018 primarily due to strength in new product sales. Sales within our Sealing Solutions platform decreased in the second quarter of 2019 compared to the same period in 2018 primarily as a result of weakness in the semiconductor and automotive end markets. Sales within our Micropump platform decreased in the second quarter of 2019 compared to the same period in 2018 due to weakness in the core printing and hemodialysis end markets. Sales within our Material Processing Technologies platform decreased slightly in the second quarter of 2019 compared to the same period in 2018 primarily due to timing of projects and unfavorable foreign currency translation.

Operating income of $56.8 million and operating margin of 24.4% in the second quarter of 2019 were higher than the $52.6 million and 23.1%, respectively, recorded during the same period in 2018, primarily due to higher volume and lower amortization, partially offset by higher engineering investments.

Fire & Safety/Diversified Products Segment
(In thousands)
Three Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
164,043

 
$
164,300

Operating income
43,614

 
45,882

Operating margin
26.6
%
 
27.9
%

Sales of $164.0 million were relatively flat in the second quarter of 2019 compared to the same period in 2018. This reflects a 3% increase in organic sales offset by a 3% unfavorable impact from foreign currency translation. In the second quarter of 2019, sales increased 4% domestically and decreased 4% internationally compared to the same period in 2018. Sales to customers outside the U.S. were approximately 52% of total segment sales in the second quarter of 2019 compared to 54% during the same period in 2018.

Sales within our Dispensing platform decreased in the second quarter of 2019 compared to the same period in 2018 primarily due to large projects in the U.S. from 2018 not repeating in 2019, weakness in Asian markets and unfavorable foreign currency translation. Sales within our Band-It platform increased in the second quarter of 2019 compared to the same period in 2018 due to strength in the aerospace market. Sales within our Fire & Safety platform increased in the second quarter of 2019 compared to the same period in 2018 due to strong demand for core pump/modules with OEMs.

Operating income $43.6 million and operating margin of 26.6% in the second quarter of 2019 were lower than the $45.9 million and 27.9%, respectively, recorded during the same period in 2018, mainly due to product mix and higher engineering investments.

Consolidated Results for the Six Months Ended June 30, 2019 Compared with the Same Period in 2018
(In thousands)
Six Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
1,264,330

 
$
1,246,684

Operating income
303,065

 
284,514

Operating margin
24.0
%
 
22.8
%

For the six months ended June 30, 2019, Fluid & Metering Technologies contributed 39% of sales, 43% of operating income and 42% of EBITDA; Health & Science Technologies contributed 36% of sales, 32% of operating income and 34% of EBITDA; and Fire & Safety/Diversified Products contributed 25% of sales, 25% of operating income and 24% of EBITDA. These percentages are calculated on the basis of total segment (not total Company) sales, operating income and EBITDA.

34

Table of Contents



Sales in the first six months of 2019 were $1,264.3 million, which was a 1% increase compared to the same period in 2018. This reflects a 3% increase in organic sales, partially offset by a 2% unfavorable impact from foreign currency translation. Sales to customers outside the U.S. represented approximately 50% of total sales in the first six months of 2019 compared to 51% during the same period in 2018.

Gross profit of $576.2 million in the first six months of 2019 increased $12.2 million, or 2%, compared to the same period in 2018, while gross margin of 45.6% in the first six months of 2019 increased 40 basis points from 45.2% during the same period in 2018. Both gross profit and margin increased compared to the prior year period primarily due to price, volume leverage and productivity initiatives, partially offset by higher engineering costs.

Selling, general and administrative expenses decreased to $271.0 million in the first six months of 2019 from $275.9 million during the same period in 2018, primarily due to lower amortization and variable compensation costs in 2019 as well as the stamp duty charge in 2018. Corporate costs decreased to $37.8 million in the first six months of 2019 compared to $42.1 million during the same period in 2018 primarily due to lower amortization and variable compensation costs in 2019 as well as the stamp duty charge in 2018. As a percentage of sales, selling, general and administrative expenses were 21.4% for the first six months of 2019, down 70 basis points compared to 22.1% during the same period in 2018.

The Company incurred $2.1 million of restructuring expenses in the first six months of 2019 compared with $3.6 million during the same period in 2018. The restructuring expenses were part of initiatives that support the implementation of key strategic efforts designed to facilitate long-term, sustainable growth through cost reduction actions primarily consisting of employee reductions and facility rationalization.

Operating income of $303.1 million and operating margin of 24.0% in the first six months of 2019 were up from the $284.5 million and 22.8%, respectively, recorded during the same period in 2018. The increases in operating income and operating margin are primarily due to gross margin expansion and lower selling, general and administrative expenses.

Other (income) expense - net was $0.5 million of income in the first six months of 2019 compared to $4.5 million of income during the same period in 2018, primarily due to foreign currency transaction gains in 2018 that did not repeat in 2019.

Interest expense of $21.9 million in the first six months of 2019 was essentially flat compared to the same period in 2018.

The provision for income taxes decreased to $58.2 million in the first six months of 2019 compared to $60.8 million during the same period in 2018. The effective tax rate decreased to 20.7% in the first six months of 2019 compared to 22.8% during the same period in 2018 due to an increase in foreign tax credits as a result of U.S. Treasury proposed regulations issued related to Global Intangible Low-Taxed Income (“GILTI”), discrete income tax expense in the first quarter of 2018 related to IRS Revenue Procedure 2018-17 and IRS Notice 2018-26 and the mix of global pre-tax income among jurisdictions.

Net income of $223.5 million in the first six months of 2019 increased from $206.1 million during the same period in 2018. Diluted earnings per share of $2.92 in the first six months of 2019 increased $0.27, or 10%, compared to the same period in 2018.

Fluid & Metering Technologies Segment
(In thousands)
Six Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
488,711

 
$
475,133

Operating income
146,012

 
137,394

Operating margin
29.9
%
 
28.9
%

Sales of $488.7 million increased $13.6 million, or 3%, in the first six months of 2019 compared to the same period in 2018. This reflects a 5% increase in organic sales, partially offset by a 2% unfavorable impact from foreign currency translation. In the first six months of 2019, sales increased 2% domestically and 4% internationally compared to the same period in 2018. Sales to customers outside the U.S. were approximately 43% of total segment sales in both the first six months of 2019 and 2018.

Sales within our Pumps platform increased in the first six months of 2019 compared to the same period in 2018 due to strength in OEM activity and LACT projects. Sales within our Valves platform increased in the first six months of 2019 compared to the same period in 2018 primarily due to strong demand within the chemical end market. Sales within our Water platform increased

35

Table of Contents


in the first six months of 2019 compared to the same period in 2018 due to increased project demand domestically and in Asia. Sales within our Energy platform increased in the first six months of 2019 compared to the same period in 2018 primarily as a result of new product launches along with a favorable North American aviation market. Sales within our Agriculture platform decreased in the first six months of 2019 compared to the same period in 2018 due to decreased demand across both OEM and distribution channels in North America and Europe.
 
Operating income of $146.0 million and operating margin of 29.9% in the first six months of 2019 were higher than the $137.4 million and 28.9%, respectively, recorded in the first six months of 2018, primarily due to higher volume and productivity initiatives.

Health & Science Technologies Segment
(In thousands)
Six Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
457,543

 
$
448,478

Operating income
110,917

 
104,375

Operating margin
24.2
%
 
23.3
%

Sales of $457.5 million increased $9.1 million, or 2%, in the first six months of 2019 compared to the same period in 2018. This reflects a 3% increase in organic sales and a 1% increase from an acquisition (FLI - July 2018), partially offset by a 2% unfavorable impact from foreign currency translation. In the first six months of 2019, sales increased 7% domestically and decreased 2% internationally compared to the same period in 2018. Sales to customers outside the U.S. were approximately 55% of total segment sales in the first six months of 2019 compared to 57% during the same period in 2018.

Sales within our Scientific Fluidics & Optics platform increased in the first six months of 2019 compared to the same period in 2018 due to new product introductions, increased demand for IVD, biotechnology, DNA sequencing and defense and the FLI acquisition. Sales within our Gast platform increased in the first six months of 2019 compared to the same period in 2018 primarily due to new product introductions in the food and beverage market. Sales within our Material Processing Technologies platform decreased in the first six months of 2019 compared to the same period in 2018 primarily due to timing of large projects in 2019 as compared to 2018. Sales within our Sealing Solutions platform decreased in the first six months of 2019 compared to the same period in 2018 due to market softness in the semiconductor and automotive end markets. Sales within our Micropump platform decreased in the first six months of 2019 compared to the same period in 2018 due to industrial distribution softness.
    
Operating income of $110.9 million and operating margin of 24.2% in the first six months of 2019 were higher than the $104.4 million and 23.3%, respectively, recorded during the same period in 2018, primarily due to lower amortization, partially offset by higher engineering investments.

Fire & Safety/Diversified Products Segment
(In thousands)
Six Months Ended 
 June 30,
 
2019
 
2018
Net sales
$
320,202

 
$
323,473

Operating income
83,942

 
85,436

Operating margin
26.2
%
 
26.4
%

Sales of $320.2 million decreased $3.3 million, or 1%, in the first six months of 2019 compared to the same period in 2018. This reflects a 2% increase in organic sales offset by a 3% unfavorable impact from foreign currency translation. In the first six months of 2019, sales increased 4% domestically and decreased 5% internationally compared to the same period in 2018. Sales to customers outside the U.S. were approximately 52% of total segment sales in the first six months of 2019 compared with 54% during the same period in 2018.

Sales within our Dispensing platform decreased in the first six months of 2019 compared to the same period in 2018 due to large projects in the U.S. from 2018 not repeating in 2019. Sales within our BAND-IT platform increased in the first six months of 2019 compared to the same period in 2018 due to strength in the aerospace market. Sales within our Fire & Safety platform increased in the first six months of 2019 compared to the same period in 2018 primarily due to elevated OEM backlog and strong demand for rescue tools across all geographies.


36

Table of Contents


Operating income of $83.9 million and operating margin of 26.2% in the first six months of 2019 were lower than the $85.4 million and 26.4%, respectively, recorded during the same period in 2018, primarily due to higher engineering investments.

37

Table of Contents


Liquidity and Capital Resources

Operating Activities

Cash flows from operating activities for the first six months of 2019 increased $27.4 million, or 14%, to $219.8 million compared to the first six months of 2018 due to higher earnings and favorable operating working capital. At June 30, 2019, working capital was $855.1 million and the Company’s current ratio was 3.4 to 1. At June 30, 2019, the Company’s cash and cash equivalents totaled $543.2 million, of which $341.2 million was held outside of the United States.

Investing Activities

Cash flows used in investing activities for the first six months of 2019 decreased $1.4 million to $24.5 million compared to the same period in 2018 primarily due to proceeds from the disposal of fixed assets.

Cash flows from operations were more than adequate to fund capital expenditures of $25.7 million and $21.0 million in the first six months of 2019 and 2018, respectively. Capital expenditures were generally for machinery and equipment that supported growth, improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. Management believes that the Company has ample capacity in its plants and equipment to meet demand increases for future growth in the intermediate term.

Financing Activities

Cash flows used in financing activities for the first six months of 2019 were $118.6 million compared to $72.0 million during the same period in 2018, primarily as a result of higher share repurchases and dividends paid in 2019.

On June 13, 2016, the Company completed a private placement of a $100 million aggregate principal amount of 3.20% Senior Notes due June 13, 2023 and a $100 million aggregate principal amount of 3.37% Senior Notes due June 13, 2025 (collectively, the “Notes”) pursuant to a Note Purchase Agreement, dated June 13, 2016 (the “Purchase Agreement”). Each series of Notes bears interest at the stated amount per annum, which is payable semi-annually in arrears on each June 13th and December 13th. The Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other unsecured, unsubordinated debt. The Company may at any time prepay all, or any portion of the Notes; provided that such portion is greater than 5% of the aggregate principal amount of the Notes then outstanding. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole amount. In addition, the Company may repurchase the Notes by making an offer to all holders of the Notes, subject to certain conditions.

On May 31, 2019, the Company entered into a credit agreement (the “Credit Agreement”) along with certain of its subsidiaries, as borrowers (the “Borrowers”), Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, with other agents party thereto. The Credit Agreement consists of a revolving credit facility (the “Revolving Facility”), which is an $800.0 million unsecured, multi-currency bank credit facility expiring on May 30, 2024. The Credit Agreement replaces the Company’s existing five-year, $700 million credit agreement, dated as of June 23, 2015, which was due to expire in June 2020. At June 30, 2019, there was no balance outstanding under the Revolving Facility and $9.1 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility of $790.9 million.

Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the better of the Company’s senior, unsecured, long-term debt rating or the Company’s applicable leverage ratio. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the last day of the applicable interest period selected, or every three months from the effective date of such interest period for interest periods exceeding three months. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments pursuant to such increases may not exceed $400 million.

The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and the Notes, a minimum interest coverage ratio of 3.00 to 1 and a maximum leverage ratio of 3.50 to 1. In the case of the leverage ratio, there is an option to increase the ratio to 4.00 for 12 months in connection with certain acquisitions. At June 30, 2019, the Company was in compliance with both of these financial covenants, as the Company’s interest coverage ratio was 15.98 to 1 and

38

Table of Contents


the leverage ratio was 1.25 to 1. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes; however, both are subject to cross-default provisions.

On December 1, 2015, the Company’s Board of Directors approved an increase of $300.0 million in the authorized level for repurchases of common stock. This followed the prior Board of Directors approved repurchase authorization of $400.0 million that was announced by the Company on November 6, 2014. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Facility. During the six months ended June 30, 2019, the Company repurchased a total of 389 thousand shares at a cost of $54.7 million. During the six months ended June 30, 2018, the Company repurchased a total of 147 thousand shares at a cost of $20.5 million, of which $1.0 million settled in July 2018. As of June 30, 2019, the amount of share repurchase authorization remaining is $322.3 million.

The Company believes current cash, cash from operations and cash available under the Revolving Facility will be sufficient to meet its operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, authorized share repurchases and annual dividend payments to holders of the Company’s common stock for the remainder of 2019. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings.

Non-GAAP Disclosures

Set forth below are reconciliations of Adjusted operating income, Adjusted net income, Adjusted EPS, EBITDA and Adjusted EBITDA to the comparable measures of net income and operating income, as determined in accordance with U.S. GAAP. We have reconciled Adjusted operating income to Operating income; Adjusted net income to Net income; Adjusted EPS to EPS; and consolidated EBITDA, segment EBITDA, Adjusted EBITDA and Adjusted segment EBITDA to Net income. The reconciliation of segment EBITDA to net income was performed on a consolidated basis due to the fact that we do not allocate consolidated interest expense or the consolidated provision for income taxes to our segments.

EBITDA means earnings before interest, income taxes, depreciation and amortization. Given the acquisitive nature of the Company, which results in a higher level of amortization expense from recently acquired businesses, management uses EBITDA as an internal operating metric to provide another representation of the businesses’ performance across our three segments and for enterprise valuation purposes. Management believes that EBITDA is useful to investors as an indicator of the strength and performance of the Company and a way to evaluate and compare operating performance and value companies within our industry. Management believes that EBITDA margin is useful for the same reason as EBITDA. EBITDA is also used to calculate certain financial covenants, as discussed in Note 10 in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, “Financial Statements.”

This report references organic sales, a non-GAAP measure, that refers to sales from continuing operations calculated according to U.S. GAAP but excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first twelve months of ownership or divestiture. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers.

Management uses Adjusted operating income, Adjusted net income, Adjusted EBITDA and Adjusted EPS as metrics by which to measure performance of the Company since they exclude items that are not reflective of ongoing operations, such as restructuring expenses. Management also supplements its U.S. GAAP financial statements with adjusted information to provide investors with greater insight, transparency and a more comprehensive understanding of the information used by management in its financial and operational decision making.

In addition to measuring our cash flow generation and usage based upon the operating, investing and financing classifications included in the Condensed Consolidated Statements of Cash Flows, we also measure free cash flow (a non-GAAP measure) which represents net cash provided by operating activities minus capital expenditures. We believe that free cash flow is an important measure of operating performance because it provides management a measurement of cash generated from operations that is

39

Table of Contents


available for mandatory payment obligations and investment opportunities, such as funding acquisitions, paying dividends, repaying debt and repurchasing our common stock.

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.
1. Reconciliations of the Change in Net Sales to Organic Net Sales
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
IDEX
Change in net sales
1
 %
 
2
 %
 
 %
 
1
 %
- Impact from acquisitions/divestitures
 %
 
1
 %
 
 %
 
 %
- Impact from foreign currency
(2
)%
 
(2
)%
 
(3
)%
 
(2
)%
Change in organic net sales
3
 %
 
3
 %
 
3
 %
 
3
 %
 
Six Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
IDEX
Change in net sales
3
 %
 
2
 %
 
(1
)%
 
1
 %
- Impact from acquisitions/divestitures
 %
 
1
 %
 
 %
 
 %
- Impact from foreign currency
(2
)%
 
(2
)%
 
(3
)%
 
(2
)%
Change in organic net sales
5
 %
 
3
 %
 
2
 %
 
3
 %
2. Reconciliations of Reported-to-Adjusted Operating Income and Margin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(dollars in thousands)
Three Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
74,146

 
$
56,763

 
$
43,614

 
$
(19,240
)
 
$
155,283

 + Restructuring expenses
930

 
330

 
819

 
47

 
2,126

Adjusted operating income (loss)
$
75,076

 
$
57,093

 
$
44,433

 
$
(19,193
)
 
$
157,409

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
246,189

 
$
232,253

 
$
164,043

 
$
(386
)
 
$
642,099

 
 
 
 
 
 
 
 
 
 
Operating margin
30.1
%
 
24.4
%
 
26.6
%
 
n/m

 
24.2
%
Adjusted operating margin
30.5
%
 
24.6
%
 
27.1
%
 
n/m

 
24.5
%
 
Three Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
71,228

 
$
52,569

 
$
45,882

 
$
(21,848
)
 
$
147,831

 + Restructuring expenses
343

 
1,123

 
267

 
255

 
1,988

Adjusted operating income (loss)
$
71,571

 
$
53,692

 
$
46,149

 
$
(21,593
)
 
$
149,819

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
242,800

 
$
227,403

 
$
164,300

 
$
(143
)
 
$
634,360

 
 
 
 
 
 
 
 
 
 
Operating margin
29.3
%
 
23.1
%
 
27.9
%
 
n/m

 
23.3
%
Adjusted operating margin
29.5
%
 
23.6
%
 
28.1
%
 
n/m

 
23.6
%

40

Table of Contents


 
Six Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
146,012

 
$
110,917

 
$
83,942

 
$
(37,806
)
 
$
303,065

 + Restructuring expenses
930

 
330

 
819

 
47

 
2,126

Adjusted operating income (loss)
$
146,942

 
$
111,247

 
$
84,761

 
$
(37,759
)
 
$
305,191

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
488,711

 
$
457,543

 
$
320,202

 
$
(2,126
)
 
$
1,264,330

 
 
 
 
 
 
 
 
 
 
Operating margin
29.9
%
 
24.2
%
 
26.2
%
 
n/m

 
24.0
%
Adjusted operating margin
30.1
%
 
24.3
%
 
26.5
%
 
n/m

 
24.1
%
 
Six Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Reported operating income (loss)
$
137,394

 
$
104,375

 
$
85,436

 
$
(42,691
)
 
$
284,514

 + Restructuring expenses
486

 
2,182

 
367

 
595

 
3,630

Adjusted operating income (loss)
$
137,880

 
$
106,557

 
$
85,803

 
$
(42,096
)
 
$
288,144

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
475,133

 
$
448,478

 
$
323,473

 
$
(400
)
 
$
1,246,684

 
 
 
 
 
 
 
 
 
 
Operating margin
28.9
%
 
23.3
%
 
26.4
%
 
n/m

 
22.8
%
Adjusted operating margin
29.0
%
 
23.8
%
 
26.5
%
 
n/m

 
23.1
%
3. Reconciliations of Reported-to-Adjusted Net Income and EPS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands, except EPS)
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Reported net income
$
113,209

 
$
107,126

 
$
223,477

 
$
206,084

 + Restructuring expenses
2,126

 
1,988

 
2,126

 
3,630

 + Tax impact on restructuring expenses
(560
)
 
(494
)
 
(560
)
 
(873
)
Adjusted net income
$
114,775

 
$
108,620

 
$
225,043

 
$
208,841

 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2019
 
2018
 
2019
 
2018
Reported EPS
$
1.48

 
$
1.38

 
$
2.92

 
$
2.65

 + Restructuring expenses
0.03

 
0.03

 
0.03

 
0.05

 + Tax impact on restructuring expenses
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.01
)
Adjusted EPS
$
1.50

 
$
1.40

 
$
2.94

 
$
2.69

 
 
 
 
 
 
 
 
Diluted weighted average shares
76,387

 
77,704

 
76,334

 
77,722


41

Table of Contents


4. Reconciliations of EBITDA to Net Income
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(dollars in thousands)
Three Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Operating income (loss)
$
74,146

 
$
56,763

 
$
43,614

 
$
(19,240
)
 
$
155,283

- Other (income) expense - net
239

 
80

 
(140
)
 
(557
)
 
(378
)
+ Depreciation and amortization
5,640

 
9,635

 
3,717

 
172

 
19,164

EBITDA
79,547

 
66,318

 
47,471

 
(18,511
)
 
174,825

- Interest expense
 
 
 
 
 
 
 
 
11,011

- Provision for income taxes
 
 
 
 
 
 
 
 
31,441

- Depreciation and amortization
 
 
 
 
 
 
 
 
19,164

Net income

 

 

 
 
 
$
113,209

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
246,189

 
$
232,253

 
$
164,043

 
$
(386
)
 
$
642,099

Operating margin
30.1
%
 
24.4
%
 
26.6
%
 
n/m

 
24.2
%
EBITDA margin
32.3
%
 
28.6
%
 
28.9
%
 
n/m

 
27.2
%
 
Three Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Operating income (loss)
$
71,228

 
$
52,569

 
$
45,882

 
$
(21,848
)
 
$
147,831

- Other (income) expense - net
511

 
(463
)
 
(45
)
 
(53
)
 
(50
)
+ Depreciation and amortization
5,707

 
10,090

 
3,597

 
176

 
19,570

EBITDA
76,424

 
63,122

 
49,524

 
(21,619
)
 
167,451

- Interest expense
 
 
 
 
 
 
 
 
11,140

- Provision for income taxes
 
 
 
 
 
 
 
 
29,615

- Depreciation and amortization
 
 
 
 
 
 
 
 
19,570

Net income
 
 
 
 
 
 
 
 
$
107,126

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
242,800

 
$
227,403

 
$
164,300

 
$
(143
)
 
$
634,360

Operating margin
29.3
%
 
23.1
%
 
27.9
%
 
n/m

 
23.3
%
EBITDA margin
31.5
%
 
27.8
%
 
30.1
%
 
n/m

 
26.4
%
 
Six Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Operating income (loss)
$
146,012

 
$
110,917

 
$
83,942

 
$
(37,806
)
 
$
303,065

- Other (income) expense - net
317

 
364

 
365

 
(1,564
)
 
(518
)
+ Depreciation and amortization
11,146

 
19,142

 
7,179

 
356

 
37,823

EBITDA
156,841

 
129,695

 
90,756

 
(35,886
)
 
341,406

- Interest expense
 
 
 
 
 
 
 
 
21,932

- Provision for income taxes
 
 
 
 
 
 
 
 
58,174

- Depreciation and amortization
 
 
 
 
 
 
 
 
37,823

Net income
 
 
 
 
 
 
 
 
$
223,477

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
488,711

 
$
457,543

 
$
320,202

 
$
(2,126
)
 
$
1,264,330

Operating margin
29.9
%
 
24.2
%
 
26.2
%
 
n/m

 
24.0
%
EBITDA margin
32.1
%
 
28.3
%
 
28.3
%
 
n/m

 
27.0
%

42

Table of Contents


 
Six Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
Operating income (loss)
$
137,394

 
$
104,375

 
$
85,436

 
$
(42,691
)
 
$
284,514

- Other (income) expense - net
645

 
(1,060
)
 
(3,666
)
 
(418
)
 
(4,499
)
+ Depreciation and amortization
11,401

 
21,479

 
7,371

 
373

 
40,624

EBITDA
148,150

 
126,914

 
96,473

 
(41,900
)
 
329,637

- Interest expense
 
 
 
 
 
 
 
 
22,140

- Provision for income taxes
 
 
 
 
 
 
 
 
60,789

- Depreciation and amortization
 
 
 
 
 
 
 
 
40,624

Net income
 
 
 
 
 
 
 
 
$
206,084

 
 
 
 
 
 
 
 
 
 
Net sales (eliminations)
$
475,133

 
$
448,478

 
$
323,473

 
$
(400
)
 
$
1,246,684

Operating margin
28.9
%
 
23.3
%
 
26.4
%
 
n/m

 
22.8
%
EBITDA margin
31.2
%
 
28.3
%
 
29.8
%
 
n/m

 
26.4
%
5. Reconciliations of EBITDA to Adjusted EBITDA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(dollars in thousands)
Three Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
EBITDA
$
79,547

 
$
66,318

 
$
47,471

 
$
(18,511
)
 
$
174,825

+ Restructuring expenses
930

 
330

 
819

 
47

 
2,126

Adjusted EBITDA
$
80,477

 
$
66,648

 
$
48,290

 
$
(18,464
)
 
$
176,951

 

 

 

 
 
 

Adjusted EBITDA margin
32.7
%
 
28.7
%
 
29.4
%
 
n/m

 
27.6
%
 
Three Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
EBITDA
$
76,424

 
$
63,122

 
$
49,524

 
$
(21,619
)
 
$
167,451

+ Restructuring expenses
343

 
1,123

 
267

 
255

 
1,988

Adjusted EBITDA
$
76,767

 
$
64,245

 
$
49,791

 
$
(21,364
)
 
$
169,439

 
 
 
 
 
 
 
 
 
 
Adjusted EBITDA margin
31.6
%
 
28.3
%
 
30.3
%
 
n/m

 
26.7
%
 
Six Months Ended June 30, 2019
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
EBITDA
$
156,841

 
$
129,695

 
$
90,756

 
$
(35,886
)
 
$
341,406

+ Restructuring expenses
930

 
330

 
819

 
47

 
2,126

Adjusted EBITDA
$
157,771

 
$
130,025

 
$
91,575

 
$
(35,839
)
 
$
343,532

 
 
 
 
 
 
 
 
 
 
Adjusted EBITDA margin
32.3
%
 
28.4
%
 
28.6
%
 
n/m

 
27.2
%
 
Six Months Ended June 30, 2018
 
FMT
 
HST
 
FSDP
 
Corporate
 
IDEX
EBITDA
$
148,150

 
$
126,914

 
$
96,473

 
$
(41,900
)
 
$
329,637

+ Restructuring expenses
486

 
2,182

 
367

 
595

 
3,630

Adjusted EBITDA
$
148,636

 
$
129,096

 
$
96,840

 
$
(41,305
)
 
$
333,267

 

 
 
 
 
 
 
 
 
Adjusted EBITDA margin
31.3
%
 
28.8
%
 
29.9
%
 
n/m

 
26.7
%


43

Table of Contents


6. Reconciliations of Cash Flows from Operating Activities to Free Cash Flow
 
 
 
 
 
 
 
 
 
 
(dollars in thousands)
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Cash flows from operating activities
$
131,175

 
$
120,697

 
$
219,838

 
$
192,426

- Capital expenditures
12,867

 
10,959

 
25,742

 
20,968

Free cash flow
$
118,308

 
$
109,738

 
$
194,096

 
$
171,458


Critical Accounting Policies

As discussed in the Annual Report on Form 10-K for the year ended December 31, 2018, the preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. See Part 1, Notes to the Condensed Consolidated Financial Statements, Note 1 Basis of Presentation and Significant Accounting Policies. The adoption of recent accounting standards as described in Note 1 had a material impact on our condensed consolidated balance sheet due to the recognition of right of use assets and lease liabilities but did not have and is not expected to have a material impact on our condensed consolidated results of operations or cash flows. Aside from recent accounting standards adopted as described in Note 1, there have been no changes to the Company’s critical accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2018 that have a material impact on our condensed consolidated financial statements.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates. The Company may, from time to time, enter into foreign currency forward contracts and interest rate swaps on its debt when it believes there is a financial advantage in doing so. A treasury risk management policy, adopted by the Board of Directors, describes the procedures and controls over derivative financial and commodity instruments, including foreign currency forward contracts and interest rate swaps. Under the policy, the Company does not use financial or commodity derivative instruments for trading purposes, and the use of these instruments is subject to strict approvals by senior officers. Typically, the use of derivative instruments is limited to foreign currency forward contracts and interest rate swaps on the Company’s outstanding long-term debt. As of June 30, 2019, the Company did not have any derivative instruments outstanding.

Foreign Currency Exchange Rates

The Company’s foreign currency exchange rate risk is limited principally to the Euro, Swiss Franc, British Pound, Canadian Dollar, Indian Rupee and Chinese Renminbi. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. The effect of transaction gains and losses is reported within Other (income) expense-net in the Condensed Consolidated Statements of Operations.

Interest Rate Fluctuation

The Company does not have significant interest rate exposure due to substantially all of the $849.0 million of debt outstanding as of June 30, 2019 being fixed rate debt.

Item 4.    Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15(b) promulgated under the Securities Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded as of June 30, 2019, that the Company’s disclosure controls and procedures were effective.


44

Table of Contents


There has been no change in the Company’s internal controls over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.


45

Table of Contents


PART II. OTHER INFORMATION
 
Item 1.    Legal Proceedings

The Company and its subsidiaries are party to legal proceedings as described in Note 19 in Part I, Item 1, “Legal Proceedings,” and such disclosure is incorporated by reference into this Item 1, “Legal Proceedings.” In addition, the Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims have been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about the Company’s purchases of its common stock during the quarter ended June 30, 2019:
Period
Total Number of
Shares Purchased
 
Average Price
Paid per Share
 
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans
or Programs(1)
 
Maximum Dollar
Value that May Yet
be Purchased
Under the Plans
or Programs(1)
April 1, 2019 to April 30, 2019
19,143

 
$
154.73

 
19,143

 
$
322,342,564

May 1, 2019 to May 31, 2019

 

 

 
322,342,564

June 1, 2019 to June 30, 2019

 

 

 
322,342,564

Total
19,143

 
$
154.73

 
19,143

 
$
322,342,564

 
(1)
On December 1, 2015, the Company’s Board of Directors approved an increase of $300.0 million in the authorized level of repurchases of common stock. This followed the prior Board of Directors approved repurchase authorization of $400.0 million that was announced by the Company on November 6, 2014. These authorizations have no expiration date.


46

Table of Contents


Item 6.    Exhibits.

Exhibit
Number
 
Description
 
 
 
10.1
 
Credit Agreement, dated as of May 31, 2019, by and among IDEX Corporation and certain of its subsidiaries, as borrowers, Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit; JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association, as co-syndication agents and issuers of letters of credit; HSBC Bank USA, National Association, Mizuho Bank, Ltd., PNC Bank, National Association, and U.S. Bank, National Association, as co-documentation agents, and the other lenders and financial institutions party thereto (incorporated by reference to Exhibit No. 10.1 to the Current Report of IDEX on Form 8-K filed June 4, 2019, Commission File No. 1-10235)
 
 
 
*31.1
 
 
 
*31.2
 
 
 
*32.1
 
 
 
*32.2
 
 
 
*101
 
The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Shareholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.
 
 
 
*104
 
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
 
 
 
* Filed herewith



47

Table of Contents


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
IDEX Corporation
 
 
 
 
By:
/s/ WILLIAM K. GROGAN
 
 
William K. Grogan
 
 
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
 
 
 
 
By:
/s/ MICHAEL J. YATES
 
 
Michael J. Yates
 
 
Vice President and Chief Accounting Officer
(Principal Accounting Officer)
Date: July 26, 2019

48
Exhibit


Exhibit 31.1
Certification of Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
I, Andrew K. Silvernail, certify that:
1. I have reviewed this quarterly report on Form 10-Q of IDEX Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
 
 
 
/s/ ANDREW K. SILVERNAIL
 
 
Andrew K. Silvernail
 
 
Chairman of the Board and Chief Executive Officer
Date: July 26, 2019


Exhibit


Exhibit 31.2
Certification of Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
I, William K. Grogan, certify that:
1. I have reviewed this quarterly report on Form 10-Q of IDEX Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
 
 
 
/s/ WILLIAM K. GROGAN
 
 
William K. Grogan

 
 
Senior Vice President and Chief Financial Officer
Date: July 26, 2019


Exhibit


Exhibit 32.1
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of IDEX Corporation (the “Company”) hereby certifies, to such officer's knowledge, that:
(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
/s/ ANDREW K. SILVERNAIL
 
 
Andrew K. Silvernail
 
 
Chairman of the Board and Chief Executive Officer
Date: July 26, 2019



Exhibit


Exhibit 32.2
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of IDEX Corporation (the “Company”) hereby certifies, to such officer's knowledge, that:
(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
/s/ WILLIAM K. GROGAN
 
 
William K. Grogan
 
 
Senior Vice President and Chief Financial Officer
Date: July 26, 2019